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OUTLINES 
Background of my PhD program is primarily based on the use of nuclear magnetic 
resonance spectroscopy (NMR) as a versatile tool that can be applied for several 
biological purposes. 
During the early years of my PhD, I mainly used proton detection nuclear magnetic 
resonance techniques (1H-NMR) for the identification and characterization of 
molecules that can act as potential drugs. Since, GPCRs are targeted by approximately 
45% to 50% of medicinal drugs, I focused my attention on the development and 
conformational analysis of peptides modulating a few of these receptors bringing to 
different therapeutic effects. 
During the last period of my PhD, I used NMR spectroscopy techniques based on 15N 
and/or 13C detection. Techniques suitable to study much larger systems as whole 
proteins. I applied in-cell, in extracts and in vitro NMR spectroscopy techniques to 
study and monitor in a qualitative and quantitative manner biological reactions that 
can occur on a protein into a biological environment. In particular, I studied the 
intracellular fate of oxidized α‑synucein molecules. 
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ABBREVIATIONS 
Abbreviations used for amino acids and designation of peptides follow the rules of the 
IUPAC-IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 1972, 247, 977-
983. Amino acid symbols denote L-configuration unless indicated otherwise. The 
following additional abbreviations are used: 
1D, 2D and 3D, one-, two- and three-dimensional; Boc, tert-butyloxycarbonyl; Bzl, benzyl; 
cAMP, Cyclic adenosine monophosphate; DCM, dichloromethane;; DIPEA, N,N-
diisopropylethyl-amine; DMF, N,Ndimethylformamide; DMSO, dimethylsulfoxide; DPC, dodecyl 
phosphocholine; DQF-COSY, double quantum filtered correlated spectroscopy; EL, extracellular 
loop; EM, energy minimization; ESI-MS, electrospray ionization-mass spectrometry; Fmoc, 9-
fluorenylmethoxycarbonyl; GPCR, G-protein-coupled receptor; HBTU, 2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HOBt, Nhydroxy-benzotriazole; hU-II, 
human Urotensin-II peptide; h-UTR, human Urotensin II receptor; IL, intracellular loop; LC, 
liquid chromatography; MD, molecular dynamic; Nal, Naphtylalanine; NMR, nuclear magnetic 
resonance; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser enhancement 
spectroscopy; Orn, Ornitine;; Pen, penicillamine; POMC, proopiomelanocortin; PVDF, 
polivinilidenfluoruro ; RMSD, root mean square deviation; ROESY, rotating-frame Overhauser 
effect spectroscopy; RP-HPLC, reverse phase-high performance liquid chromatography; r-UTR, 
rat Urotensin II receptor; SAR, Structure activity relationship; SD, standard deviation; SDS, 
sodium dodecylsulphate; SDS-PAGE, Sodium Dodecyl Sulphate-PolyAcrylamide Gel 
Electrophoresis; HMQC; Heteronuclear Multiple-Quantum Correlation, SUVs, small unilamellar 
vesicles; SPPS, solid phase peptide synthesis; TBS-T, Tris-Buffered Saline and Tween 20; TES, 
triethylsilane; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Tic, tetrahydroisoquinoline; TLC, 
thin-layer chromatography; TM, trans-membrane domain; TOCSY, total correlated 
spectroscopy; Tpi, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid; TSP, 3-
(trimethylsilanyl)propionic acid; U-II, Urotensin-II peptide. 
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CHAPTER 1-DEVELOPMENT AND CONFORMATIONAL 
ANALYSIS OF BIOACTIVE PEPTIDES MODULATING 
GPCR ACTIVITY. 
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1.1 UII/UTR SYSTEM 
INTRODUCTION 
Urotensin-II (U-II), a somatostatin-like neuropeptide, is a cyclic peptide originally 
isolated in the teleost ﬁsh Gillichthys mirabilis in the 1960s.1 Subsequently, it has been 
demonstrated that U-II is also expressed in tetrapods and that its gene is located in the 
central nervous system (CNS).2The human U-II (hU-II) consists of 11 amino acids, H-
Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH, and the whole sequence is 
recognized as the natural ligand of an orphan rat G-protein coupled receptor, ﬁrst 
named GPR14. 3 , 4 Subsequently, a human G-protein coupled receptor with 75% 
similarity to the orphan rat receptor was replicated and ﬁ nally renamed the UT 
receptor by IUPHAR.5The U-II precursor has proved to be widely expressed in various 
vertebrate species, including frogs, rats, mice, pigs, monkeys, and humans.6 In 2003, a 
paralogue of U-II, known as urotensin-related peptide (URP), was isolated in 
mammals.7 The U-II and URP genes are mostly expressed in motoneurons located in 
discrete brainstem nuclei and in the ventral horn of the spinal cord.6 U-II and URP 
mRNAs have also been detected, albeit in lower concentrations, in diﬀerent peripheral 
tissues, including the pituitary, heart, spleen, thymus, pancreas, kidney, small 
intestine, adrenal gland, and prostate.6 Also, UT receptor is widely distributed in the 
CNS and in diﬀerent organs and peripheral tissues, including cardiovascular system, 
kidney, bladder, prostate, and adrenal gland.3,8,9,10 This extensive expression turned 
out to be very important in understanding the multiple pathophysiological eﬀects in 
which the hU-II/UT receptor interaction is involved, such as cardiovascular disorders 
(heart failure, cardiac remodelling, hypertension), smooth muscle cell proliferation, 
renal disease, diabetes, and tumor growth.11 It has recently been reported that U-II 
plays an important role in pulmonary hypertension,12 modulates erectile function 
through eNOS,13 and regulates cell proliferation in prostate cancer.14 Furthermore, it 
has been demonstrated that U-II is implicated in immune inﬂammatory diseases 15and 
in many eﬀects on the CNS.16  Hence, hU-II analogues could be therapeutically 
appealing in diverse pathological disorders.17 The N-terminus portion of urotensin 
isopeptides is highly variable across animal species,18 whereas the C-terminal region, 
structurally organized in a cyclic sequence by a disul ﬁ de bridge, c[Cys-Phe-Trp-Lys-
Chapter 1 
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Tyr-Cys], is well-conserved from species to species, outlining its primary role in the 
biological activity.19 In fact, the conserved C-terminal octapeptide cyclic portion of U-II 
[hU-II(4 − 11)] retains both biological and binding properties. 
Hence, most of the peptides developed to date have been constructed on the basis of 
this sequence.20,21,22,23,24 Previously, we have identiﬁed two important analogues of 
hU-II(4 − 11), speciﬁcally, the superagonist 1 (P5U), H-Asp-c[Pen-Phe-Trp-Lys-Tyr-Cys]-
Val-OH,25 and the antagonist urantide, H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 26, 
which are nowadays recognized as the most potent peptide ligands at the UT receptor 
so far described. Interestingly, urantide has been extensively used not only as a valid 
tool to investigate the urotensinergic system role, but it has also been recently 
ascertained that urantide can protect against atherosclerosis in rats. 27 
In the last years, extensive nuclear magnetic resonance (NMR) and computational 
studies on both P5U and Urantide were performed. These results allowed to formulate 
a hypothesis about the structural changes that determine the switching from agonist 
to antagonist activity.28,29 To support our hypothesis and to gain new insight into the 
putative active conformation of ligands at UTR, we first replaced the Trp7 residue, 
formaly supposed to be involved in this activity switch, with a highly constrained 
analogue residue. Surprisingly, from NMR analysis of P5U and Urantide 
conformationally constrained analogues, we were able to get new insight into the 
putative active conformation of ligands at UTR, in particular we moved our attention 
from Trp7 to Tyr9. 
Later, we determined the solution conformation of urantide using a DPC membrane 
mimetic solution, instead of SDS solution used previously, and docked the obtained 
structure of urantide within a theoretical model of UTR. Conformational results were 
completely in agreement with what we found out from the constrained analogues of 
P5U and urantide, underlining the main role of Tyr9 into UTR interaction. 
As part of our ongoing effort to improve the potency and stability of urotensin-II 
analogues and to get more information about the switching between agonist and 
antagonist activity, we moved our attention from Trp7on Tyr9. In fact, we designed and 
synthesized novel analogues of P5U and urantide by the replacement of Tyr9 residue 
with aromatic noncoded amino acids. We found novel analogues with improved 
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agonist activity compared to the parent P5U and antagonist peptides alike urantide. 
Furthermore, these new ligands also showed good stability. 
Another question was still open. The two endogenous ligands, hUII and URP, both bind 
and activate UTR. Even though the two peptides share the fully conserved cyclic C-
terminal hexapeptide core sequence responsible of the biological activity, they exert 
common as well as different effects on physiological UTR's pathways. The divergent 
actions can be explained by a biased agonism concept. The idea that hU-II and URP 
interact with UTR in a distinct manner, i.e. by selecting a specific UT conformation. The 
concept of biased agonism would require specific pockets/interactions within UT 
receptor, aimed to select distinct UTR conformations that can discriminate hU-II and 
URP biological activities. To investigate the origin of the divergent activities of the two 
endogenous ligands, we performed conformational studies on URP by solution NMR 
and compared the obtained NMR structure of URP with that of hU-II previously 
determined. Finally, we undertook docking studies between URP, hU-II, and a newly 
developed UT receptor model. 
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1.1.1 New Insight into the Binding Mode of Peptides at 
Urotensin-II Receptor by Trp-Constrained Analogues of 
P5U and Urantide 
RESULTS 
Design:Pevious studies showed that hU-II analogues, which retain high affinity for UT 
receptor, all possess a type II′ β-hairpin backbone conformation regardless their 
agonist or antagonist activity, indicating that such backbone conformation is necessary 
for the UT recognition. 28,28 sopra29 The main conformational difference observed in the 
structures of the antagonists and the agonists was established in a different 
orientation of the (D/L)-Trp7 side chain. In particular, while in the agonists the (D/L)-
Trp7 indole moiety is close to the Lys8 side chain, in the antagonists (D/L)-Trp7 side 
chain is more flexible and further from the Orn side chain. Thus, we replaced the Trp 
residue with a highly constrained non coded amino acid, that is, the 2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid (Tpi) (Figure 1), to corroborate 
that hypothesis. In fact, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 
(Tpi), can only possess either gauche (+) or gauche (-) side chain rotamer populations 
since the indole moiety is cyclized to the peptide backbone Nα (Figure 1).  
 
Figure 1: Structure of Tpi amino acid 
According to our pharmacophore model, this indole orientation is only compatible 
with the antagonist conformation since the Tpi7 indole moiety is kept far from the Lys8 
side chain. Moreover, we used both L- and D-Tpi since L- and D-Trp residues are both 
compatible with UTR binding. Finally, Lys/Orn couple was shown to modulate the 
urotensin analogues activity since the Orn residue promotes antagonist activity.30 
Hence, four analogues were designed as reported in Table 1. 
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Table 1. Receptor affinity and biological activity of P5U and urantide analogues of 
general formula: 
H-Asp-c[Pen
a
-Phe-Xaa-Yaa-Tyr-Cys]-Val-OH 
 
 
 
 
 
 
a 
pKi: -log Ki   
b
 pEC50: -log EC50. 
c
 pKB (-log KB) values are from experiments in the rat thoracic aorta.  Each 
value in the table is mean ± s.e.m. of at least 4 determinations.  
 
Chemistry: Peptides were synthesized and analyzed as reported in the Experimental 
Section. The correct molecular weight of the peptide was confirmed by mass 
spectrometry and amino acid analysis (Table 1 Online Supporting Information 1.1.1).  
Biological Data: Receptor affinity at h-UTR and biological activity (rat aorta bioassay) of 
the synthesized compounds are reported in Table 1. In the same Table, P5U and 
urantide activities are reported for comparison. From the data, it can be inferred that 
peptides 1 and 2, carrying the Lys7 residue, show an agonist activity as the lead 
compound P5U. Compared to P5U, about 1.5 log reduction of the affinity and 2 log 
reduction of the activity can be observed. Conversely, peptides 3 and 4, carrying the 
Orn7 residue, show an antagonist activity as urantide, resulting in 1.8 log reduction of 
the affinity and 2 log reduction of the activity compared to the lead. Finally, the effect 
of the L- vs D-Tpi replacement is almost negligible both in the affinity and in the 
activity values. (Table 1) 
NMR Analysis: A whole set of 1D and 2D NMR spectra in 200 mM aqueous solution of 
SDS were collected for compounds 2, and 4 which differ only for the Lys to Orn residue 
at position 8 but are endowed with different activity (agonist vs antagonist, 
respectively). Complete 1H NMR chemical shift assignments were effectively achieved 
for the two peptides according to the Wüthrich procedure31 via the usual systematic 
application of DQF-COSY,3233 TOCSY,34 and NOESY experiments with the support of the 
Peptide Xaa Yaa pKi 
a pEC50 
b pKB
c 
P5U Trp Lys 9.70±0.07 9.60 ± 0.07 - 
Urantide DTrp Orn 8.30 ± 0.04 Inactive 8.30 
1 Tpi Lys 8.16 ± 0.04 7.92 ± 0.07 - 
2 DTpi Lys 8.26 ± 0.09 7.68 ± 0.17 - 
3 Tpi Orn 7.61 ± 0.11 Inactive 6.30 
4 DTpi Orn 7.43 ± 0.13 Inactive 6.28 
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XEASY software package (Online Supporting Information 1.1.1).35 Peptide 2 and 4 differ 
from P5U and Urantide, respectively, only for the Trp8 to D-Tpi residue substitution but 
they show NMR parameters different from those observed in the parent peptides 
(Tables S1 and S2, Online Supporting Information 1.1.1). In particular for the novel 
peptides, the presence of a β-turn structure along residues 6-9 can be still located 
from NOE contacts between Hα-NHi+2 of D-Tpi
7 and Tyr9 and between NH-NHi+1 of 
Lys/Orn8 and Tyr9, but the flanking regions, which in the parent peptides P5U and 
urantide folded as a short stretch of antiparallel β-sheet, are now prevalently 
disordered as indicated by all the diagnostic NMR parameters (Hα chemical shifts, NOE 
connectivities, and 3JHα-ΗN coupling constants) (Figure 2). 
Considering the side chains orientations, some interchain NOE between 
residues DTpi9, Orn8, Tyr9 and Val11 are observed. In fact, DTpi7 aromatic Hɛ3 proton 
signal (Trp nomenclature) shows NOE contacts with Lys/Orn8 side chains. Furthermore, 
Tyr9 aromatic proton signals show NOE contacts with both Lys/Orn8 and Val11 side 
chains. In peptide 4, the last interaction was stronger than in peptide 2, indicating that 
the conformer allowing a close contact between Tyr9 and Val11 side chains is more 
populated in peptide 4 than in peptide 2.  
NMR-derived constraints obtained for the analyzed peptides (Supporting 
Information 1.1.1) were used as the input data for a simulated annealing structure 
calculation. For each peptide, 20 calculated structures satisfying the NMR-derived 
constraints (violations smaller than 0.40 Å) were chosen (Figure 2 A-B). Both peptides 
2, and 4 show a distorted type II’ β-turn structure encompassing residues 6-9 
(backbone rmsd values are 0.41 and 0.37 Å, respectively). In contrast, the N- and C-
terminal residues were more flexible. Considering the side chains orientation, Lys8, and 
Tyr9 side chains showed a large preference for g- rotamer in peptide 2; Orn8 shows also 
a g- orientation in peptide 4 while Tyr9 side chain is found both in trans and g- 
conformations in this peptide. Therefore Tyr9 phenolic ring is close to Lys8 in peptide 2, 
and it points toward Val11 in peptide 4.  
Chapter 1 
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Figure 2. Superposition of the 10 lowest energy conformers of 2 (a), 4 (b). Structures were 
superimposed using the backbone heavy atoms of residues 5-10. Heavy atoms are shown with different 
colors (carbon, green; nitrogen, blue; oxygen, red; sulfur, yellow). Hydrogen atoms are not shown for 
clarity. 
 
DISCUSSION 
In our previous studies, we showed that hU-II analogues, which retain high affinity for 
UT receptor, all possess a type II′ β-hairpin backbone conformation regardless their 
agonist or antagonist activity, indicating that such backbone conformation is necessary 
for the UT recognition.2829 The main conformational difference observed in the 
structures of the antagonists and the agonists was established in a different orientation 
of the (D/L)-Trp7 side chain. In particular, while in the agonists the (D/L)-Trp7 indole 
moiety were found close to the Lys/Orn8 side chain, in the antagonists (D/L)-Trp7 side 
chain were more flexible and further from the Lys/Orn8 side chain. To corroborate our 
hypothesis, in the present work, we replaced Trp9 with a highly constrained Trp 
analogue, the Tpi residue (Figure 1). In fact, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
3-carboxylic acid (Tpi), can only possess either gauche (+) or gauche (-) side chain 
rotamer populations since the indole moiety is cyclized to the peptide backbone Nα 
(Figure 1).36 Moreover, we used both L- and D-Tpi since L- and D-Trp residues are both 
compatible with UTR binding. Finally, Lys/Orn couple was shown to modulate the 
urotensin analogues activity since the Orn residue promotes the antagonist activity.30 
Hence, four analogues (1-4) were designed as reported in Table 1. Biological data 
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showed that Lys7 containing peptides (1 and 2) are agonists, and peptides carrying the 
Orn7 (3 and 4) are antagonists. All the affinities and activities are reduced of at least 
one order of magnitude. Furthermore, L- vs D-Tpi replacement is almost negligible 
both in the affinity and in the activity values. The agonist activity of peptides 1 and 2 is 
quite unexpected since in our model (D)Tpi side chain orientation should be 
compatible only with an antagonist activity. Trying to understand this apparent 
contradiction, we performed a conformational analysis of selected peptides by solution 
NMR. We chose peptides 2 and 4 which chemically differ only for the Lys to Orn 
substitution but the activity switches from agonist to antagonist. NMR study was 
performed in SDS micelle solution. The use of SDS or DPC micelle solutions to study the 
conformational properties of hU-II analogues is motivated on the basis of their 
interaction with a membrane receptor. For peptides acting as ligands of membrane 
receptors (such as GPCRs), the use of membrane mimetic media is suggested, 
hypothesizing a membrane-assisted mechanism of interactions between the peptides 
and their receptors.37 According to this model, the membrane surface plays a key role 
in facilitating the transition of the peptide from a random coil conformation adopted in 
the extracellular environment to a conformation that is recognized by the receptor. 
The increase of the local concentration of the peptide and the reduction of the 
rotational and translational freedom of the neuropeptide are membrane-mediated 
events acting as determinant steps for the conformational transition of the peptide.38 
Indeed, micelle solutions are largely used for the conformation analysis of peptide 
hormones.61-64 In this context, we succeeded in correlating the SDS-bound 
conformation of hU-II analogues with their biological activity.39,40, 41,42 Conformational 
analysis indicated that both the peptides 2, and 4 show a distorted type II’ βturn 
structure encompassing residues 6-9. Therefore the turn structure peculiar of the 
active peptides P5U and urantide is kept in these derivatives. In contrast, the N- and C-
terminal residues of peptides 2 and 4 are highly flexible losing the short antiparallel 
beta-sheet found in P5U and urantide. Considering the side chains orientation of 
“pharmacophoric” residues (i.e., D-Tpi7, Lys8, Tyr9)24,25of peptide 2, side chains of Lys8 
and Tyr9 show a large preference for g- rotamer, hence they are spatially close while 
indole ring of D-Tpi7 is locked to a g- conformation (Figure 2A). Pharmacophoric 
distances of peptide 2 are reported in Table 2 together with those of the reference 
Chapter 1 
 12  
 
peptides P5U and urantide. According to the design, the distance between D-Tpi7 and 
Lys8 is greater than that observed in P5U. Notably, it is shorter than that observed in 
urantide. Unexpected residual agonist activity of peptide 2 indicates that its 
pharmacophoric distances still fit the agonist model although not in an ideal way. 
(Table 2) 
 
Table 2. UT-II Receptor Ligand Pharmacophoric Distances (Å)a 
a 
Reported distances were measured in the mean of 20 calculated structures. 
b 
Aryl ring centroids. 
c
 Trp 
in P5U, D-Trp in urantide. 
d
 Orn
8
 in 2, and urantide.  
 
Considering peptide 4, it was designed to fulfil the antagonist pharmacophore of UTR 
blocking the side chain of Trp7. Actually, distance between D-Tic7 and Orn8 is shorter 
than that observed in the reference antagonist urantide and is similar to the distance 
observed in peptide 2 (Table 2). Since these peptides are endowed with opposite 
activities, the distance between the positively charged nitrogen and the indole ring 
seems to be not relevant for the agonist/antagonist activity switching. Moreover, Tyr9 
side chain is preferentially trans orientated and consequently phenol ring is far from 
Orn8 and the relevant pharmacophoric distance do not fit that of urantide. Tyr9 side 
chain orientation is mainly defined by an intense NOE with Val11 methyls. To note, this 
NOE could not be observed in the NOESY spectrum of urantide due to signal 
overlapping.29,43 Hence, the correct orientation of Tyr9 for antagonist/UTR interaction 
needs to be further investigated. Studies on urantide analogues containing tyrosine 
constrained derivatives are currently in progress.  
Peptide D-Tpi7 b,c - Lys8 d Nɛ D-Tpi7 b,c - Tyr9 b Lys8 Nɛ - Tyr9 b 
2 7.9 11.0 6.5 
P5U e 6.2 7.9 5.8 
4 7.8 10.6 9.3 
Urantide e 8.9 11.1 5.7 
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Figure3. Superposition of the lowest energy conformer of (A) compound 2 (green) with P5U (azure) and 
(B) compound 4 (green) with urantide(yellow). Structures were superimposed using the backbone heavy 
atoms of residues 6 – 9. Backbones are evidenced as a ribbon. 
CONCLUSIONS 
In conclusion, using Trp-constrained analogues of P5U and urantide we obtained new 
insight on the binding mode of agonists and antagonists at the UT receptor. In 
particular, Lys8/Orn8 replacement is confirmed to be the key substitution for the 
agonist to antagonist switching. Conformationally, a type II’ β-turn structure 
encompassing residues 6-9 was confirmed as structural element of active compounds. 
Considering the three points pharmacophore model, the distance between the 
positively charged nitrogen and the indole ring seems to be not relevant for the 
agonist/antagonist activity switching. In contrast, a different orientation of the side 
chain of Tyr9 present in the analogues investigated in this study could be a factor that 
plays a crucial role in agonist/antagonis activity. In particular, the long distance 
between the phenol ring and the Orn8 nitrogen atom, observed in the antagonist 
peptide 4 is unprecedent in our studies. 
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1.1.2 Urantide Conformation and Interaction with Urotensin-II 
Receptor  
RESULTS  
NMR Analysis: A whole set of 1D and 2D NMR spectra in 200 mM aqueous solution of 
DPC were collected for Urantide. Complete 1H NMR chemical shift assignments were 
effectively achieved for the peptide according to the Wüthrich procedure.31  
A qualitative analysis of short- and medium-range nuclear Overhauser effects (NOEs), 
3JNH-Hα coupling constants, NH exchange rates, and temperature coefficients for 
exchanging NH indicated that Urantide show stable secondary structure in DPC 
micelles (Online Supporting Information1.1.2, Table S2). In particular, NOE contacts 
between Hα-NHi+2 of D-Trp
7 and Tyr9 and between NH-NHi+1 of Orn
8 and Tyr9 indicated 
the presence of a β-turn. This result was supported by the observation of slowly 
exchanging NH resonance of residue 9, and low value of the temperature coefficient 
for this proton (-ΔΔδ/ΔT < 3.0 ppb/K). A short stretch of antiparallel β-sheet involving 
residues 5-6 and 10-11 is inferred from a number of long-range NOEs including Hα-NH 
connectivities between residues 5, 11 and 10, 6 and a NH-NH connectivity between 
residues 6 and 9. All the data indicated the presence of a β-hairpin structure. 
Considering the side chains orientations, Urantide shows interchain NOEs between 
residues D-Trp7 and Orn8, and between Phe6 and Val11. Furthermore, Tyr9 aromatic 
proton signals show NOE contacts with both Orn8 and Val11 side chains. The last 
interaction was relatively strong, indicating that the conformer bearing a close contact 
between Tyr9 and Val11 side chains is highly populated.  
NOE-derived constraints obtained for Urantide (Table S3) were used as the input data 
for a simulated annealing structure calculation. 10 calculated structures satisfying the 
NMR-derived constraints (violations smaller than 0.40 Å) were chosen for further 
analysis (Figure 1). Urantide shows a type II’ β-hairpin structure encompassing residues 
5-10 (backbone rmsd value is 0.17 Å). Considering the side chains orientation, D-Trp7 
and Lys8 side chains showed a large preference for trans and g- rotamer, respectively. 
χ2 dihedral angle of D-Trp
7 was 125° or -70°  (χ2 = -67° in the lowest energy 
conformation) in accordance with strong NOEs between Hα and H3 or H1, respectively 
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(Online Supporting Information1.1.2, Table S3). Finally, Tyr9 is found both in trans and 
g- conformations, with a prevalence of the trans rotamer. Therefore D-Trp7 indole is 
close to Lys8, and Tyr9 phenolic ring points toward Val11. Obtained conformations are in 
accordance with the measured 3JHN-Hα and 
3JHα-Hβ coupling constants (Online Supporting 
Information1.1.2, Table S2). 
 
 
Figure 1. Stereoview of the lowest energy conformer of urantide. Backbone is evidenced as a ribbon. 
Side chains of the 10 lowest energy conformers are also shown as mesh surface.  
 
Docking Studies: The theoretical structure of the h-UT receptor was generated by 
homology modeling based on the crystal structure of bovine rhodopsin (PDB code 
1F88)44, as described previously.43 The resulting structure represents an inactive form 
of the h-UT receptor with an overall conformation very similar to that of bovine 
rhodopsin (1.22 Å rmsd between the backbone atoms of the transmembrane domains) 
and to the β2-adrenergic receptor (β2AR, PDB code 2RH1).
45 Calculations converged 
towards a single solution in which the lowest energy binding conformation was also 
belonging to the most populated cluster and remarkably stable throughout the 
molecular dynamic (MD) simulations. As shown in Figure 2a, the hypothetical binding 
site of Urantide is located among TM-III÷TM-VII, EL-II and EL-III. The β-hairpin is 
oriented along the receptor helical axis, with the N- and C-terminal residues pointing 
towards the extracellular side. The binding mode of the peptide is determined mainly 
by the interactions showed in Figure 2b and Table 2. In particular, (i) a tight charge-
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reinforced hydrogen-bonding network involving the carboxylate group of Asp130 and 
the protonated -amino group of Orn8 of Urantide is established. (ii) Two hydrophobic 
pockets, delimited by residues listed in Table 2, host the aromatic side chains of Phe6 
and D-Trp7, of Urantide. Particularly, the indole system of D-Trp7 appears to be 
optimally oriented for a π-stacking interaction with the aromatic indole system of 
Trp275. (iii) The phenolic OH of Tyr9 is at hydrogen-bonding distance with the 
backbone CO of Ala289. (iv) Asp4 in Urantide is involved in a hydrogen-bonding 
network. (v) Finally, the negatively charged C-terminal group establishes two hydrogen 
bonds with backbone HN of Cys123 and Cys 199, and a salt bridge with the protonated 
guanidinium moiety of Arg189. All the aforementioned interactions resulted to be 
quite stable during the whole MD production run (data not shown).  
Table 2. Urantide/h-UTR Interactions 
Residue* Surrounding residue 
Asp
4
 Ala187 (EL-II), Met188 (EL-II), Cys199 (EL-II), Arg206 (EL-II), Ala207 (EL-II) 
Pen
5
 Leu200 (EL-II), Ala207 (EL-II), Leu212 (TM-V), Gln278 (TM-VI) 
Phe
6
 Cys123 (EL-I), Val184 (TM-IV), Met188 (EL-II), Cys199 (EL-II)  
D-Trp
7
 Phe131 (TM-III), Met134 (TM-III), His135 (TM-III), Leu212 (TM-V), Phe216 (TM-V), Ile220 
(TM-V), Trp275 (TM-VI), Gln278 (TM-VI) 
Orn
8
 Asp130 (TM-III), Phe274 (TM-VI), Gln278 (TM-VI), Thr301 (TM-VII), Thr304 (TM-VII) 
Tyr
9
 Leu288 (EL-III), Ala289 (EL-III). 
Cys
10
 Cys199 (EL-II), Pro287 (EL-III), Leu288 (EL-III). 
Val
11
 Val121(EL-I), Cys123 (EL-I), Arg189 (EL-II), Leu198 (EL-II), Cys199 (EL-II), Leu288 (EL-III). 
* For sake of clarity, the residue numbers of the ligands are reported as apex while those of the receptor 
are not. 
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Figure 2. (a) h-UTR model complexed with Urantide. Receptor backbones are represented in grey and 
labeled. (b) Urantide within the binding pocket of h-UTR. Hydrogen bonds are shown as dotted lines. 
 
DISCUSSION 
In our previous studies, we showed that all hU-II analogues, which retain high affinity 
for UT receptor, all possess a type II′ β-hairpin backbone conformation regardless their 
agonist or antagonist activity, indicating that such backbone conformation is necessary 
for the UT recognition.28,29 We hypothesized that the main conformational difference 
observed in the structures of the antagonists and the agonists was a different 
orientation of the (D/L)-Trp7 side chain. This hypothesis has been challenged by recent 
results about the activity of P5U and Urantide analogues in which the Trp9 was 
replaced by the highly constrained analogue Tpi (See 1.1.1) Tpi (2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylic acid), can only possess gauche side chain rotamer 
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populations since the indole moiety is cyclized to the peptide backbone Nα 36. 
Nevertheless, we found derivatives showing both agonist and antagonist activity only 
depending on the presence of Lys (agonist) or Orn (antagonist) at position 8. 
Conformational analysis indicated that the main difference between agonist and 
antagonist 3D structure was the orientation of the Tyr9 side chain which was gauche- 
oriented in the agonist P5U and trans oriented in the antagonist Urantide. 
Consequently phenol ring is close to Lys8 or far from Orn8, respectively. Tyr9 side chain 
orientation is mainly defined by NOEs with Lys8/Orn8 or Val11 side chain signals. In our 
previous conformational study on the lead antagonist Urantide29 we found a gauche- 
orientation for Tyr9 side chain but, the above mentioned NOE could not be observed in 
its NOESY spectrum due to signal overlapping. In the cited work 43, NMR study was 
performed in sodium dodecylsulphate (SDS) micelle solution, which is largely used for 
the conformation analysis of peptide hormones.46,47,48  Here trying to avoid the 
overlapping problems, we repeated the conformational analysis of Urantide using 
another micelle solution, i.e. dodecylphosphocholine (DPC). Also DPC solutions are 
commonly used for peptide hormones 49,50 and antimicrobial peptides studies. NMR 
data obtained using a DPC solution are very similar to those obtained in SDS solution, 
but luckily signals show a better dispersion. In particular, for Urantide the NOE 
between Orn8 and Val11 side chains are clearly visible. Urantide structure obtained 
from these NOEs (Figure 1) showed Tyr9 both in trans and g- conformations, with a 
prevalence of the trans rotamer. Therefore Tyr9 phenolic ring is close to Val11 in 
Urantide accordingly to the results recently found for constrained analogues (See 
1.1.1). Furthermore, D-Trp7 side chain is stably in trans conformation as derived by the 
strong NOEs between its indole moiety and the Orn8 side chain. This was more flexible 
in the Urantide structure obtained in SDS. Again, signal overlapping in the NOESY 
spectrum acquired in the last medium can explain the observed differences.  
To gain insight into the interaction mode, the new structure of Urantide was 
docked within a model of human Urotensin II (receptor h-UTR) that we recently built.43 
The binding mode of the peptide is determined mainly by the interactions showed in 
Figure 2b and Table 2 and described in the Results section. The main difference, 
compared to the previously obtained model complex,43 is observed in the interactions 
of the Tyr9 side chain, as expected from the starting NMR ligand structure. A 
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superposition of the two models is shown in Figure S1 (Online Supporting Information 
1.1.2). Tyr9 side chain points towards the third extracellular loops and forms a stable 
hydrogen bond with the backbone carbonyl of Ala289. In contrast, Tyr9 side chain 
pointed towards the intracellular side of the receptor in the old model. An intriguing 
difference is that the Tyr9 side chain is now highly exposed to the solvent while before 
it was hidden in a hydrophobic pocket. Interestingly, the Urantide/UTR complex model 
described here shows comparable energy to the previously obtained (Table 3) but it is 
in higher accordance with the current experimental data.  
Table 3. Binding free energies (ΔGAD4) calculated for the energy minimized averaged 
complexes deriving from the MD simulations. 
Receptor Ligand ΔGbind
a Electrb H-Bondb VdWb Desolvb Torsb 
h-UTR Urantide -22.74 -4.94 -5.35 -25.91 7.49 5.97 
h-UTRc Urantide -24.33 -4.99 -5.90 -26.50 7.09 5.97 
a
ΔGbind: free energy of binding. 
b
Energy terms contributing to the AutoDock4 scoring function. Electr: 
electrostatic; H-Bond: H-Bonding; VdW: Van der Waals; Desolv: desolvation; Tors: torsional entropy. All 
terms are given in kcal/mol.  
 
Based on the binding mode of UTR/Urantide, we derived a new 3D 
pharmacophore model for peptide antagonists illustrated in Figure 3. Distances 
between Tyr phenol moiety and Trp indole or Orn N are longer than those reported 
previously for Urantide in SDS solution 43 but in good accordance with those recently 
reported for a highly constrained analogue of the same peptide (See 1.1.1).  
 
Figure 3. Stereoview of the pharmacophore model for peptide antagonists at UTR. The distances 
between the aryl ring centroids of (D)Trp
7
 and Tyr
9
, and the N of Orn
8
, are displayed. Distances and 
standard deviations are obtained from one hundred structures saved every 10 ps of the MD simulations.  
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CONCLUSIONS 
In conclusion, we determined the solution conformation of Urantide using DPC as 
membrane mimetic environment and obtained a complex model of Urantide within a 
theoretical model of UTR. A new three points pharmacophore model has also been 
developed. Complex model and pharmacophore can help the next design cycle of 
novel peptide and small-molecule antagonists at UTR.  
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1.1.3 Lead Optimization of P5U and Urantide: Discovery of 
Novel Potent Ligands at the Urotensin-II Receptor 
RESULTS 
Design. A SAR study on Tyr9 was prompted by our recent finding that the side chain 
orientation of this residue influences the activity of P5U(1) and urantide constrained 
analogues.(See 1.1.1) Hence we replaced Tyr with aromatic non-coded amino acids 
(Figure 1). Non-coded amino acids were chosen in an attempt to improve the serum 
stability. We started with bulky electron-rich aromatic moieties in compounds 2-7 or 
phenyl ring substituted with bulky chlorine atoms (8-11). Alternatively, electron 
donating hydroxyl group of the Tyr9 was replaced by electron withdrawing groups such 
as cyano (12-13) or nitro (14-15) (Table 1). Peptides were synthesized and analyzed as 
reported in the Experimental Section and Supporting Information (Online Supporting 
Information1.1.3, Tables S1 and S2). 
 
Figure 1. General view of synthesized compounds. 
 
Biological Data. Sequences, receptor binding affinity at h-UT and biological activity (rat 
aorta bioassay) of the designed compounds are reported in Table 1. To evaluate the 
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suitable features of the aromatic residue in position 9 and, in particular, the 
contribution of the phenolic group, we replaced Tyr9 with several aromatic uncoded 
amino acids (Figure 1), in both sequences of P5U (1) and urantide (compounds 2-15). 
Firstly, we used amino acids with a bulkier aromatic group, that is, (1)Nal, (2)Nal and 
Btz. The substitution of the native Tyr9 residue in P5U by a (2)Nal residue (compound 
2), generated an analogue of similar contractile potency (pEC50 9.14±0.06, Figure S1) 
and a reduced binding affinity of 1 log unity (pKi 8.70±0.08). Similar modification in 
urantide sequence produced compound 3 with improved binding affinity when 
compared to urantide (pKi 9.14±0.08). Anyway, this compound retains a small residual 
agonist activity (Emax 13±5 %). Compound 4 [(1)Nal/Tyr replacement in P5U] showed to 
be an agonist less potent than P5U (pEC50 8.3±0.2, Emax 86±5 %) although it showed 
good receptor affinity (pKi 9.40). The same substitution [(1)Nal/Tyr replacement]  was 
introduced in the urantide sequence to give compound 5 with a partial agonist activity 
(pEC50 7.74±0.10, Emax 37±9 %). In
 compound 6, we replaced Tyr9 with a residue of 
benzothiazolylalanine (Btz), an analogue of Trp in which the indole group is replaced by 
a benzothiazolyl moiety which is a highly electron-rich system. Compound 6 showed to 
be significantly (p<0.05) more potent agonist compared to P5U (pEC50 10.71±0.04, Emax 
89±16 %). In parallel, compound 7 (Btz9 derivative of urantide) showed an increased 
partial agonist activity (Emax 57±2 %) compared to analogues 3 and 5. 
Then, Tyr9 residue was replaced with some aromatic amino acids containing an 
isoster of phenolic group in para position. Replacing the Tyr9 residue in P5U with the 
amino acid (pCl)Phe led to a compound with similar activity to the parent peptide. In 
fact, compound 8 showed a comparable potency in functional assay (pEC50 9.09±0.12, 
Emax 85±10 %) albeit with a slight reduction in binding affinity at UT receptor (pKi 
8.91±0.07). Instead, compound 9 resulted in a weak partial agonist (Emax 13±3 %) with 
an improved binding affinity profile (pKi 8.98±0.05). 
Interestingly, replacing the Tyr9 residue with the amino acid (3,4-Cl)Phe generated the 
compound 10 with a high agonist activity (pEC50 10.9±0.14, p<0.05 compared to P5U; 
Emax 102±8 %) resulting it a superagonist. As expected, this compound is about 1.6 log 
more potent than P5U and represents the most potent peptide agonist at UT receptor 
discovered to date. Compound 11, (3,4-Cl)Phe9 derivative of urantide, similarly to 
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compound 9 resulted in a partial agonist with increased efficacy compared to the last 
(Emax 26±7 vs 13±3 %). Phenolic OH group was then replaced by electron withdrawing 
groups in compounds 12-15. Compound 12, in which Tyr9 was replaced with a 
(pCN)Phe residue resulted to be less potent as agonist compared to P5U (pEC50 8.97, 
Emax 79±1) and with a reduced binding affinity (pKi 8.74±0.10). Interestingly, compound 
13, (pCN)Phe9 derivative of urantide, showed a behaviour as an antagonist producing a 
parallel rightward shift (Online Supporting Information1.1.3, Figure S2 panel A) of the 
agonist response curves without depressing the agonist Emax. Schild-plot analysis was 
consistent with competitive antagonism (Slope = 0.918, 95% c.l. 0.758-1.080) and a pKB 
value of 8.15±0.05 was calculated (Online Supporting Information1.1.3, Figure S2 panel 
B) comparable to that of urantide (Table 1). Finally, replacing the Tyr9 residue with the 
amino acid (pNO2)Phe, led to compounds with similar activity compared to the 
respective parent peptides. In fact, compound 14 was shown to have agonist activity 
comparable to P5U (1) (pKi 8.75±0.05, pEC50 9.20±0.08, Emax 95±20%) and compound 
15 revealed a behaviour as an antagonist comparable to urantide producing a parallel 
rightward shift of the agonist response curves. Also for this compound Schild-plot 
analysis was consistent with competitive antagonism (Slope = 0.900, 95% c.l. 0.660-
1.140) and a pKB value of 8.12±0.07 was calculated (Online Supporting 
Information1.1.3, Figure S2 panel C, D) (Table 1).  
Table 1. Receptor Affinity and Biological Activity of P5U and urantide Analogues of General Formula: 
H-Asp-c[Pena-Phe-Xaa-Yaa-R-Cys]-Val-OH 
 
a
 Cys in hU-II and hU-II(4-11); 
b
 Binding assay with recombinant human UT receptor and radioligand 
[125I]Urotensin-II pKi: -log Ki; 
c
 Contractile activity in a rat aorta bioassay, pEC50: -log EC50; 
d
 percent 
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versus hU-II; 
e
 pKB: log(CR-1)-log[B]. Each value in the table is mean ± S.E.M. of at least 3-4 
determinations. 
f
 For hU-II, N-terminus  = H-Glu-Thr-Pro-Asp. 
g
 For the structure of unconventional 
amino acids see Figure 1. 
h
p<0.05 vs. hU-II Emax (Two-tail Student’s t-test for paired data). 
i
p<0.05 vs. P5U 
(ANOVA and Dunnett’s post hoc test). 
j
p<0.05 vs. hU-II (Two-tail Student's t-test for paired data). n.a., 
not active; n.d., not determinable. 
 
The ability of the newly discovered antagonist analogues to stimulate calcium 
mobilization like urantide was also evaluated. Both peptides 13 and 15 behave as 
partial agonist in this assay showing an increased efficacy compared to urantide. The 
intracellular calcium assay was performed according to the manufacturer’s protocol 
(DiscoveRx Corporation, Fremont, CA) described in the Experimental Section. Results 
are reported in Table 2. 
Table 2. Intracellular Calcium Efficacy 
Code Ca++ efflux efficacy in %a 
1 µM 10 µM 
Urantide 43.3±0.8 46.2±0.6 
12 61.4±1.5* 61.7±3.3 
14 56.5±0.2* 61.2±3.8 
a
Efﬁcacy is expressed as % of the maximum response to hU-II. Each value in the table is mean ± S.E.M. of 
3 determinations. * = p<0.05 vs. the respective value of urantide (ANOVA and Dunnett’s post hoc test 
 
Peptides Stability: To investigate the effects of the modifications of peptides on 
proteolytic susceptibility, the disappearance of the intact peptides incubated in diluted 
serum at 37 °C was followed by RP-HPLC (Online Supporting Information1.1.3, Figure 
S3);51,52 peptides hU-II(4-11), urantide, P5U(1), 10 and 13 were assayed. Overall results, 
shown in Figure 2, display the course of degradation up to 36 h to highlight the 
differences in the profiles of the degraded peptides. After 16hs of treatment, hU-II(4-
11) had a residual concentration lower than 50%, for P5U about 65%, while for other 
compounds it was higher than 70% of the initial concentration. After 36hs, compound 
10 showed a residual concentration higher than 50%, while for P5U(1) the 
concentration was slightly lower (about 45%). Clearly, developed peptides are very 
stable in 25% FCS.  
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Figure 2. The resistance to enzyme degradation of hU-II(4-11), urantide, P5U(1), 10 and 13 was assessed 
by incubation in 25% FCS for 36 h. Residual peptide quantity, expressed as the percentage of the initial 
amount versus time (h), was plotted. The results represent the average of three independent 
experiments.  
 
NMR Analysis:  A whole set of 1D and 2D NMR spectra in 200 mM aqueous solution of 
SDS were collected for compounds 10, and 13. These peptides were chosen since 
compound 10 behaves as a superagonist compared to P5U(1) while compound 13 is a 
potent antagonist devoid of agonist activity in the rat aorta assay (Table 1). 
Complete 1H NMR chemical shift assignments were effectively achieved for the two 
peptides according to the Wüthrich procedure.31 (Online Supporting Information1.1.3, 
Tables S3-S4). Peptide 10 differs from P5U only for the (3,4-Cl)Phe/Tyr9 substitution 
and peptide 13 differs from urantide only for the (pCN)Phe/Tyr9 substitution. Indeed, 
they show diagnostic NMR parameters (Hα proton chemical shifts, NOE contacts, and 
3JNH-Hα coupling constants, NH exchange rates and temperature coefficients) all similar 
to those observed in the corresponding parent peptides (Online Supporting 
Information1.1.3, Tables S3-S6). In particular, NOE contacts between Hα-NHi+2 of 
(D)Trp7 and residue 9 and between NH-NHi+1 of Lys(Orn)
8 and residue 9 indicated the 
presence of a β-turn. This result was supported by the observation of slowly 
exchanging NH resonance of residue 9, and low value of the temperature coefficient 
for this proton (-Δδ/ΔT < 3.0 ppb/K). A short stretch of antiparallel β-sheet involving 
residues 5-6 and 10-11 is inferred from a number of long-range NOEs including Hα-NH 
connectivities between residues 5, 11 and 10, 6 and a NH-NH connectivity between 
residues 6 and 9. All the data indicated the preservation, in 10 and 13, of the β-hairpin 
structure. As for the parent peptides, a number of NOE interactions connect (D)Trp7 
with Lys(Orn)8 side chains indicating a close proximity between them (Online 
Supporting Information1.1.3, Figures S4-S5). (3,4-Cl)Phe side chain of peptide 10 shows 
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NOE contacts with Lys8 (Online Supporting Information1.1.3, Figure S4). In contrast, 
(pCN)Phe9 of peptide 13 has intense NOE contacts with Val11 side chain and only a 
weak NOE with Orn8 Hγ’s (Online Supporting Information1.1.3, Figure S5). These results 
point to a different orientation of residue 9 side chain in the two peptides. NMR-
derived constraints obtained for the analyzed peptides (Online Supporting 
Information1.1.3, Tables S5 and S6) were used as the input data for a simulated 
annealing structure calculation. For each peptide, 20 calculated structures satisfying 
the NMR-derived constraints (violations smaller than 0.20 Å) were chosen (Figure 3 a-
b). As shown, both the peptides 10, and 13 show a well defined type II’ β-hairpin 
structure encompassing residue 5-10 (backbone rmsd values are 0.36 and 0.27 Å, 
respectively). In contrast, the N- and C-terminal residues were more flexible.  
Considering the side chains orientation, Phe6, (D)Trp7, and Orn8 χ1 angles 
showed a large preference for trans, trans, and g- rotamers, respectively. In urantide, 
dihedral angle χ2 of DTrp
7 was about 125° or -70° in accordance with strong NOEs 
between Hα and H3 or H1, respectively (Online Supporting Information1.1.3, Table S6). 
Finally, side chain of residue 9 is found preferentially in g- and in trans orientation in 
peptide 10 and 13, respectively.  
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Figure 3. Stereoview of the superposition of the 10 lowest energy conformers of 10 (a), 13 (b). 
Structures were superimposed using the backbone heavy atoms of residues 5-10. Heavy atoms are 
shown with different colours (carbon, green; nitrogen, blue; oxygen, red; sulfur, yellow; chlorine, 
magenta). Hydrogen atoms are not shown for clarity. 
 
DISCUSSION 
As part of our ongoing efforts in improving the potency and stability of urotensin 
analogues discovered previously in our laboratories and the knowledge about their 
SARs, we have designed and synthesized a series of analogues of P5U (1) and urantide 
in which the Tyr9 residue was replaced with aromatic non-coded amino acids (Table 1). 
Tyr9 belongs to the WKY pharmacophoric sequence of U-II which is crucial for 
interaction with its receptor as demonstrated by previous studies. In fact, the 
replacement of W, K, and Y induces large changes in biological activity, suggesting the 
importance of the side chains of these residues for binding to and activating the U-II 
receptor.20,21,22,53,54,55,56 In this study the phenol moiety of P5U and urantide  was 
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replaced with bulky electron-rich aromatic moieties in compounds 2-7 or phenyl ring 
substituted with bulky chlorine atoms (8-11). Alternatively, electron donating hydroxyl 
group of the Tyr9 was replaced by electron withdrawing groups such as cyano (12-13) 
or nitro (14-15). All synthesized compounds were tested for their binding affinity on h-
UT-transfected CHO cells and for their contractile activity on de-endothelialized rat 
aortic rings (Table 1).26 Overall, bioactivity results (Table 1) indicate that in the P5U 
derivatives the substitution of Tyr9 with other aromatic-based moieties is well 
tolerated. In fact, all these compounds gave a rat aorta contraction of at least 70%. 
These SARs are in accordance with previous results,19,21 which demonstrated that Tyr9 
in hU-II or hU-II(4-11) can be replaced by various aromatic residues preserving most of 
the agonist activity, at least when the flexibility of Tyr9 side chain is kept.57 The best 
results in the P5U(1) derivatives were obtained replacing tyrosine by bulky Btz (6) or 
(3,4-Cl)Phe (10) residues significantly improving in both cases the potency of more 
than one log (pEC50 = 10.71 and 10.9, respectively, p<0.05 vs. P5U) compared to P5U 
(pEC50 = 9.4±0.2), and more than two logs compared to the endogenous agonist hU-II 
(pEC50 = 8.50±0.06). To note that peptide 10 is the most potent UT agonist discovered 
to date. We and others21,43 have shown that bulky aromatic amino acids may increase 
the binding affinity and the biological activity of the U-II agonists through an 
enhancement of the hydrophobic interactions within a putative Tyr binding pocket of 
UT. 
To the best of our knowledge and considering the urantide derivatives SAR 
studies on position 9 are unprecedented. Like P5U(1), urantide seems also to tolerate 
aromatic substitutions at position 9; as a matter of fact, all derivatives bind to UT 
receptor with pKi ≥ 7.77. The main result obtained in this series is the finding of two 
antagonists: compounds 13, and 15. Despite a slight loss of affinity, these compounds 
behave as pure antagonists in the rat aorta bioassay as the parent urantide. SAR data 
clearly indicate that small polar groups (pCN, pNO2 and the original OH) are requested 
for pure antagonist activity. In contrast, bulky lipophilic moieties [(1)Nal, (3,4-Cl)Phe, 
Btz] increase the agonist activity (efficacy) of urantide derivatives.  
As widely discussed elsewhere,29 urantide behaves as a partial agonist in a 
calcium mobilization assay performed in CHO cells expressing the h-UT.58 The same 
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behaviour was shown by compounds 13 and 15, i.e. pure antagonist in the aorta assay 
and partial agonist in a calcium mobilization assay, although with slightly higher 
efficacy compared to urantide (Table 2). Nevertheless, it is well known that urantide 
has been used by several groups as reference antagonist compound in studies of the 
urotensinergic system.27,59,60,61 These novel ligands can be useful to discriminate the 
partial agonism/antagonism effects at the UT receptor in different cell lines/tissues. 
Also, the availability of novel agonists and antagonists as pharmacological tools to 
investigate the urotensinergic system is very important since subtle pharmacokinetic 
differences can differentiate their effects in vivo . In this respect, stability tests were 
performed on peptide hU-II(4-11), P5U, urantide and derivatives 10 and 13. These 
studies demonstrated that urantide and peptides 10, and 13 are highly stable showing 
a residual concentration higher than 50% in fetal calf serum even after 36 h (Figure 2). 
The higher level of stability shown by urantide, P5U, 10 and 13 compared to hU-II may 
be tentatively ascribed to the presence of a Pen residue which can hinder the 
reduction of the disulfide bridge. The effect on serum stability of aromatic non-coded 
amino acid is variable being 10 more stable than P5U while 13 less stable than 
urantide. 
A conformational analysis by solution NMR of the most interesting derivatives 10 and 
13 was also carried out. In previous works,28,29 we showed that hU-II analogues, which 
retain high affinity for UT receptor, all possess a type II’ β-hairpin backbone 
conformation regardless their agonist or antagonist activity, indicating that such 
backbone conformation is necessary for the UT recognition. Indeed, such backbone 
conformation is observed also in the novel derivatives (Figure 3) confirming the above 
outcome. The main conformational difference observed in the structures of peptide 10 
(agonist activity) and peptide 13 (antagonist activity) is established in a different 
orientation of the (3,4-Cl)Phe or (pCN)Phe side chain, respectively. In particular, while 
in the agonist 10 the (3,4-Cl)Phe9 is close to the Lys8 side chain (Figures 3a and S4 
Online Supporting Information1.1.3), in the antagonist 13 (pCN)Phe9 side chain is close 
to the Val11 side chain and far from the Orn8 side chain (Figures 3b and S5, Online 
Supporting Information1.1.3). This result is in accordance with the one obtained 
studying constrained analogues of P5U and urantide(See 1.1.1) and with a revision of 
the conformational preferences of urantide performed using DPC micelles. (See 1.1.2) 
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In particular, we demonstrated (See 1.1.1) that while the orientation of the Trp7 indole 
moiety is irrelevant for the agonist/antagonist activity switching, the Tyr9 phenol 
orientation influences peptide activity. To note that, signals spread of the 1H NMR 
resonances of both 10 and 13 is better than that observed in the spectra of the 
published hU-II analogues with less overlapping which led to a higher number of 
experimental constraints and structure reliability. 
CONCLUSIONS 
Analogues of P5U(1) and urantide modified at Tyr9 position were developed. Two of 
them, compounds 6 and 10, showed increased potency compared to the parent 
superagonist peptide P5U(1). Two urantide analogues, compounds 13 and 15, turned 
out to be pure antagonists in the rat aorta bioassay likewise parent urantide. 
Compounds 10 and 13 showed also a good stability in serum proteolytic assay, 
suggesting that these peptides may be stable enough to give them an additional 
opportunity in drug delivery. Furthermore, these novel analogues allowed to improve 
the knowledge on structure- and conformation-activity relationships on UT receptor 
ligands which can help in the design of improved compounds.  
Ultimately, these novel ligands such as the superagonist 9 which is the most potent 
agonist discovered to date, could be useful pharmacological tools for in vitro and in 
particular in vivo  studies aimed at clarifying the role played by the U-II/UT system in 
physiopathological conditions. 
  
Chapter 1 
 31  
 
1.1.4 An Investigation into the Origin of the Biased Agonism 
Associated with the Urotensin-II Receptor Activation 
 
RESULTS 
Chemistry. Exact molecular weight of the peptide was proved by mass spectrometry 
and amino acid analysis (Online Supporting Information1.1.4, Table S1). 
NMR Analysis. 1D and 2D NMR spectra were collected in water and 200 mM aqueous 
solution of SDS for URP. Complete 1H NMR chemical shifts assignment was 
accomplished according to the Wüthrich procedure31  (Online Supporting 
Information1.1.4, Tables S2 and S3) 
Considering the spectra in water solution, many NMR parameters indicate structural 
flexibility (Online Supporting Information1.1.4, Table S2). For example, Hα chemical 
shift values are all close (<0.1 ppm) to the corresponding ones in random coil 
peptides62 apart that of Lys8 (for easy comparison, peptide numbering of URP follows 
that of hU-II).  
In contrast, NMR parameters derived from spectra acquired in SDS micelles are typical 
of a structured peptide (Online Supporting Information1.1.4, Table S3). Furthermore 
such parameters indicated that URP structure is similar to other UTR ligands previously 
studied by us, especially to its paralog hU-II. For comparison purpose, Hα chemical 
shifts of residues of hU-II constituting the cyclic moiety common to URP are also 
reported in Table S3 (Online Supporting Information1.1.4). In particular, NOE contacts 
between Hα-NHi+2 of Trp
7 and Tyr9 and between NH-NHi+1 of Lys
8 and Tyr9 indicated the 
presence of a β-turn. The observation of slowly exchanging NH resonance of residue 9, 
and low value of the temperature coefficient for this proton (-Δδ/ΔT < 3.0 ppb/K) 
confirmed this result. A number of long-range NOEs including Hα-NH connectivities 
between residues 5, 11 and 10, 6 and a NH-NH connectivity between residues 6 and 9 
supported the existence of a short stretch of antiparallel β-sheet involving residues 5-6 
and 10-11. Also, large values of 3JHN-Hα coupling constants (
3JHN-Hα > 8.0 Hz) for residues 
5, and 9-11 confirm a β-sheet structure (Online Supporting Information1.1.4, Table S3). 
Overall data supported the existence of the β-hairpin structure in URP. Furthermore, 
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many NOE interactions between Trp7 with Lys8 side chains implied that those side 
chains are close. Also, Tyr9 side chain shows NOE contacts with Lys8, while Phe6 shows 
contacts with Val11.  
Constraints derived from NMR data were used as the input for a structure calculation 
by simulated annealing. Structure calculations using NMR data from URP spectra 
acquired in water gave not converging results (backbone RMSD > 2 Å for the 10 lowest 
energy conformers; data not shown). Differently, using the NMR constraints from SDS 
micelle solution (Online Supporting Information1.1.4, Table S4), an ensemble of well 
defined structures could be obtained. In fact, the 10 lowest energy structures (Figure 2) 
showed a backbone RMSD of 0.34 Å and satisfied the NMR-derived constraints 
(violations smaller than 0.20 Å). 
 
 
Figure 2. Stereoview of the superposition of the 10 lowest energy conformers of URP. Structures were 
superimposed using the backbone heavy atoms of residues 5−10. Heavy atoms are shown with different 
colors (carbon, green; nitrogen, blue; oxygen, red; sulfur, yellow). Hydrogen atoms are not shown for 
clarity. 
 
As shown, URP folds into a type II’ β-hairpin structure along residues 5-10. Considering 
the side chains orientation, Phe6, Trp7, Lys8 and Tyr9 χ1 angles showed a high 
preference for g-, trans, g+ and g- rotamers, respectively. URP obtained NMR structure 
is very similar to those of other UTR ligands previously found by us and, in particular, to 
that of hU-II (Figure 3). 
Chapter 1 
 33  
 
 
Figure 3. Stereoview of the superposition of the lowest energy conformer of URP (color code as in Figure 
2) and hU-II (carbon atoms in grey). Structures were superimposed using the backbone heavy atoms of 
residues 5−10. 
 
h-UTR Model and Docking. A new three dimensional models of h-UTR were generated 
based on the structure of other GPCR, using the I-TASSER server.63,64,65 Five models of 
h-UTR were generated using I-TASSER server. I-TASSER output also contained top ranks 
of templates used for the structure prediction. The top template used is the high-
resolution crystal structure of human -opioid receptor (h-DOR, PDB ID: 4n6h). 66 
Other templates used for threading are the crystal structure of mouse µ-opioid 
receptor (m-MOR, PDB ID: 4dkl)67 and the crystal structure of a neurotensin receptor 1 
mutant (NTSR1, PDB ID: 4buo).68 The most important score in I-TASSER models is the 
confidence score (C-score), ranging from −5 to +2. The C-score is computed from the 
threading alignments for the estimated quality of the models. A C-score > −1.5 implies 
a model with a correct fold.69 Model 1 of h-UTR (C-score = 1.56) with higher C-scores 
was chosen as the best model and was considered for the analyses. The model 
predictions were judged using the template modelling (TM)-score and root mean-
squared difference (rmsd). The TM-score is a measure of the structural similarity 
between the model and the native structure. A TM-score > +0.5 suggests a model with 
correct topology. The TM-scores of Model 1 for h-UTR was 0.93 ± 0.06 Å. The expected 
RMSDs was 3.0 ± 2.2 Å. Additionally, to confirm the reliability of the Model 1, the 
program PROCHECK70was employed. All amino acids in the α-helices were found in the 
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favored region of the right-handed α-helix in the Ramachandran plot. There were no 
cis peptide bonds, and there were no bump regions in the calculated h-UTR models. 
The results reveal that our 3D model for h-UTR is acceptable and of high quality. Worth 
to note, the selected Model 1 maintain most of the molecular signatures which feature 
class A GPCR 71. For example, in the selected model are present 24 out of the 24 inter-
TM contacts of the consensus network found in the GPCR structures. A superposition 
of h-DOR crystal structure and h-UTR Model1 is shown in Figure S1 (Online Supporting 
Information1.1.4). 
Docking procedures using the program HADDOCK 72,73 clustered 198 structures in 2 
clusters for both the complexs h-UTR/URP and h-UTR/hU-II. Statistics and energy terms 
are reported in Table 1. Best scored complexes of h-UTR/URP and h-UTR/hU-II are 
shown in Figure 4 and 5, respectively.  
 
Table 1: Statistic and energy terms of the calculated complexes 
Complex Cluster n. H score
a
 Cluster size RMSD
b
 VdW
c
 Eletr
d
 Desolv
e
 
h-UTR/URP 1 -130.1 ± 2.6 191 0.5 ± 0.3 -56.6 ± 3.9 -150.9 ± 21.8 -49.3 ± 3.5 
h-UTR/URP 2 -102.1 ± 2.5 7 0.8 ± 0.0 -50.7 ± 2.8 -166.3 ±17.7 -28.4 ± 7.5 
h-UTR/hU-II 1 -144.2 ± 2.5 193 1.3 ± 0.0 -56.2 ± 6.5 -230.2 ± 26.2 -48.5 ± 2.5 
h-UTR/hU-II 2 -113.4 ±13.2 5 1.1 ± 0.0 -56.6 ± 4.0 -210.2 ± 10.4 -24.8 ± 9.8 
 
a
 HADDOCK score; 
b
 RMSD from the overall lowest-energy structure; 
c
 Van der Waals energy; 
d
 Electrostatic 
energy; 
e
 Desolvation energy. All terms are given in Kcal/mol. 
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Figure 4. (a) Stereoview of h-UTR model complexed with URP. URP heavy atoms are color coded as in 
Figure 2. Receptor backbones are represented in azure and labeled. (b) Stereoview of URP within the 
binding pocket of h-UTR. Hydrogen bonds are represented with dashed lines. Labels of UTR residues 
involved in previous mutagenesis studies are evidenced in red. For sake of clarity here and throughout 
the manuscript, the residue numbers of the ligands are reported as apex while those of the receptor are 
not. 
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Figure 5. (a) Stereoview of h-UTR model complexed with hU-II. hU-II heavy atoms are color coded as in 
Figure 2, apart carbon atoms which are in orange. Receptor backbones are represented in azure and 
labeled. (b) Stereoview of hU-II within the binding pocket of h-UTR. Hydrogen bonds are represented 
with dashed lines. Labels of UTR residues involved in previous mutagenesis studies are evidenced in red. 
 
DISCUSSION 
U-II and URP could exert common as well as distinct actions on cell proliferation, 
transcriptional activity, and myocardial contractile activities supporting the idea that 
U-II and URP interact with UTR in a distinct manner i.e. selecting a specific UTR 
conformation (biased agonism). 74 Biased agonism would require specific 
pockets/interactions within UTR, finalized to select distinct UTR conformations that 
may discriminate U-II and URP biological activities. It was hypothesized that a different 
conformation of the cyclic portion of the two peptides, β-turn in U-II vs γ-turn in URP, 
would cause the selection of different UTR active states, ultimately triggering a slightly 
different subset of signaling pathways.17,74 Hence, we first performed a conformational 
studies on URP by solution NMR. NMR study was performed both in water and in SDS 
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micelle solution. NMR-derived structures of URP in SDS solution are shown in Figure 2. 
Clearly, β-hairpin conformation of the backbone and the side chain cluster of the 
pharmacophoric residues Trp7, Lys8, and Tyr9, which are distinctive of UTR peptide 
agonists, are still observable in URP structure. Whereby, URP obtained NMR structure 
is very similar to those of other UTR ligands previously found by us and, in particular, 
to that of hU-II (Figure 3). It comes out that divergent actions of URP and hU-II cannot 
derive from different conformation of the ligands as hypothesized by Chatenet et al. 74 
That hypothesis was inspired by the comparison of the NMR structure of hU-II 
obtained by us in SDS micelle solution 28 and NMR structure of URP obtained by 
Chatenet et al. in water solution.19 The last structure is characterized by an inverse γ-
turn centered on the Trp-Lys-Tyr sequence as opposite to the β-turn hosted on the 
corresponding residues of hU-II. An inverse γ-turn centered on the Trp-Lys-Tyr is 
compatible with the data obtained by us in water solution, namely with a NOE contact 
between Hα-NHi+2 of Trp
7 and Tyr9. However, structure calculations using NMR data 
from URP spectra acquired in water gave not converging results (data not shown) 
probably due to a high structural flexibility of the peptide in plain buffer.   
In order to determine whether the divergent actions of URP and hU-II derive from 
different interaction with the receptor, NMR derived structures of URP and hU-II were 
docked within a model of h-UTR built by homology using the I-Tasser online 
server.63,64,65 We have already built an h-UTR model.43 It was based on the rhodopsin 
crystal structure.44 The current model is based mainly on the h-DOR crystal structure.66  
Since the last is a diffusible ligand (peptide) binding GPCR, which share higher 
sequence homology with h-UTR (TM sequence identities: 34.5% to h-DOR vs 21.8% to 
Rho), hence it can be considered a more reliable model than the previous one. In the 
docking procedures, we hypothesized that peptides bind in the extracellular side of the 
TM bundle, as observed for all the ligands of class A GPCR71and confirmed by 
mutagenesis studies.75,76,77 In this context, only the side chains of residues engaged in 
orthosteric ligand/GPCR binding in complexes with known crystal structure were 
considered flexible in the docking procedure. In particular, we took in account h-
DOR/naltrindole (PDB ID: 4n6h), m-MOR/β-funaltrexamine (PDB ID: 4dkl), and 
NTSR1/neurotensin (PDB ID: 4buo) complexes since they were used as templates by 
the unbiased homology building procedure of I-Tasser (see above). A superposition of 
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the putative binding site of h-UTR-model and h-DOR/naltrindole complex and is shown 
in Figure S2 (Online Supporting Information1.1.4) as an example. 
Best poses of complexes of h-UTR/URP and h-UTR/hU-II are shown in Figures 4 and 5, 
respectively. For both peptides, the predicted binding site is located among TM3/TM7, 
EL2, and EL3. The β-hairpin is aligned with the receptor helical axis, with the N- and C-
termina pointing toward the extracellular side. Main interactions between the 
peptides and UTR are shown in Figure 4b for h-UTR/URP and 5b for h-UTR/hU-II. These 
findings are in accordance with previous mutagenesis results.75,76,77 In fact, many of 
the receptor residues, involved in the peptides binding in our model, face the binding 
site pocket of the UT receptor as demonstrated using the substituted-cysteine 
accessibility method. For some others, the replacement with a cysteine residue caused 
a complete loss of affinity for the ligands. All these residues are evidenced in Figures 
4b-5b. Furthermore, both hU-II and URP interact with the extracellular loops (EL’s) but 
EL1 in accordance with experimental dat. 78 
Interestingly, comparing our complex model with the peptide-bound GPCR crystal 
structures solved to date (NTSR1/neurotensin79and CXCR4/CVX15, 80 it can be argued 
that hU-II (and URP, data not shown) binds to the h-UTR in a similar fashion as 
neurotensin to NTSR1 and CVX15 to CXCR4 (Figure S3, Online Supporting 
Information1.1.4). 
While the two peptides hU-II and URP share similar interactions with the receptor 
concerning the cyclic region, N-terminal region of hU-II establishes large interactions 
with extracellular loops EL2 of h-UTR. In particular, charge reinforced hydrogen bonds 
between Glu1 and Lys196 and between Asp4 and Arg193 are observable in hU-II/h-UTR 
complex (Figure 5). Those interactions cannot be present in URP/h-UTR complex. In 
agreement with our model, dissociation kinetics experiments revealed a putative 
interaction between UTR and the glutamic residue at position 1 of hU-II. Indeed, it was 
observed that the replacement of this residue by an alanine, i.e. [Ala1]hU-II, caused an 
increase in the dissociation rate of hU-II but not URP.  
CONCLUSIONS 
We demonstrated that distinct pathophysiological roles for URP and hU-II are not 
related to different conformations of the two peptides, but they likely arise from their 
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different interactions with the UT receptor. Those interactions can stabilize different 
active conformations of UTR which, in turn, can select specific subset of secondary 
messengers depending on the ligand-induced adopted conformation. 
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1.2 NOVEL ANALGESIC PEPTIDES WITH IMPROVED 
ANTINOCICEPTIVE PROPERTIES 
INTRODUCTION 
Since the discovery of enkephalins in 197581 thousands of opioid analogs have been 
synthesized to understand the relationship between their conformation and 
bioactivity, and to improve their pharmacological profile. Leu-enkephalin and 
Metenkephalin are involved in many physiological processes, their roles in behavior, 
neuroendocrinology and pain transmission being well documented.82,83 The use of 
enkephalins in pain treatment has been limited by the lack of metabolic stability and 
bioavailability . Several chemical approaches, such as the incorporation of d-amino 
acids, unusual amino acids, 84  cyclic moieties 85  or cyclization 86  of peptides have 
resulted in more stable enkephalin analogues. In the process of searching for new 
opioid analgesics with two active elements in one molecule, a dimeric enkephalin 
analog – biphalin, was synthesized . 87 Biphalin has been found to exhibit unique 
properties as it is 257 and 6.7 times more potent than morphine (a reference μ-
agonist) and etorphine (a ultrapotent opioid agonist), respectively, in eliciting 
antinociception when administrated intracerebroventriculary. 88 
Biphalin presents a unique structure based on two enkephalin-like branch (H- Tyr- D -
Ala-Gly-Phe, 1) linked by a hydrazine moiety (Figure 1).87,89 Its noticeable bioactivity is 
due to the peculiar structure, which has the ability to match the topographical 
requirements for both μ and δ opioid receptors. 90,91,92Furthermore, this opioid 
octapeptide induces less physical dependence and toxicities than other 
opioids.93,94,95Unfortunately, structural ﬂ exibility, scarce metabolic and chemical 
stability, low bioavailability, and distribution represent some of the major problems 
concerning the use of native opioid peptides as drugs when administered in vivo .96 
Diﬀerent approaches have been explored in an e ﬀ ort to overcome these limits, 
including the use of D-amino acids, β-homoamino acids, other types of 
nonproteinogenic residues, cyclization, and their combinations.97,98,99,100 Particularly 
appealing is the cyclization of peptides, which has been demonstrated to be a useful 
approach for developing diagnostic and therapeutic peptidic and peptidomimetic 
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drugs. Cystine or penicillamine containing cyclic peptides are often obtained by 
substituting nonbonding residues in the linear native peptide sequence with two Cys 
or Pen residues, followed by oxidation of the thiol groups.101,102,103 If compared with 
the corresponding linear peptides, cyclic derivatives have shown a great improvement 
of the conformational rigidity, premising meaningful conformational studies to 
determining the bioactive conformation. Cyclic peptides are blocked to assume the 
best conformation to interact with their speciﬁc receptors, thus the loss of internal 
rotational entropy compared to the linear analogues upon binding should be 
smaller.104,105 Cyclic peptides o ﬀ er advantages over linear peptides in terms of (i) 
stability; (ii) conformational rigidity; and (iii) suited templates for orally available small 
molecule. 92,101,102,103In the last decades we extensively studied several linear and cyclic 
biphalin analogues,106,107,108and in the present study, we pointed our attention to the 
design of two novel cyclic biphalin-like structures, as part of our program in search for 
new antinociceptive agents. This work reports the synthesis, the in vitro and in vivo  
biological activity, and the conformational analysis of two novel cyclic biphalin 
analogues 9 and 10 (Figure1). 
 
Figure 1. Structures of biphalin and derivatives 9 and 10. 
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RESULTS AND DISCUSSION 
We initiated this research with the aim to optimize the previous reported first 
cyclic model of biphalin containing a disulfide bridge. Since advantages of using 
penicillamine residues in place of cysteine were already shown, especially in the  field  
of DPDPE and its derivatives,101,109,110,111 the original design of cyclic biphalin analogues 
was modified accordingly. Thus, two novel cyclic biphalin analogues (9 and  10) were  
developed (Figure 1), and their in vitro biological activities were  tested. The analgesic 
activity of the most active model 9 was further investigated by in vivo studies. The 
cyclic final products 9 and 10 were synthesized starting from the previously reported 
tetrapeptide 2·TFA-(H-Gly-Phe-NH2) by symmetrically coupling the remaining two 
amino acids (See Scheme 1).95 It is worth noting that no protecting group was adopted 
for the side chain of the penicillamine residues, since the thiol groups were stable in 
the condition of the reactions. 
Scheme 1. Syntheses of Biphalin Analogues 9 and 10 from Tetrapeptide 2
a
 
 
a
 Reference 
97
. Compounds 3,5,7,9: Xaa = D -Pen. Compounds 4,6,8,10: Xaa = L -Pen. 
Cyclization was obtained by the oxidation of the thiols group of the D-Pen or L-Pen 
residues by a treatment of the peptides 3 and 4 with a mixture of MeOH/I2 . The 
resultant cyclic intermediate products 5 and 6 were deprotected in standard 
conditions by TFA/DCM and used for the next coupling without further puriﬁcation to 
give the ﬁnal Boc-protected products 7 and 8. Products 9 and 10 were puriﬁed as TFA 
salts. 
To determine the aﬃnity to the μ -opioid receptor (MOR),112,113 the δ-opioid 
receptor (DOR), and to the κ–opioid receptor (KOR) of compounds 9 and 10, tritiated 
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opioid peptides DAMGO([3H]-[D–Ala2,N-Me-Phe4,Gly-ol5]-enkephalin), Ile5,6deltorphin 
II, and U69593 (selective agonistsfor MOR, DOR, and KOR, respectively) were used. Ki 
values are shown in Table 1 (binding curves are shown in Figure S1, Online Supporting 
Information1.2). Analogue 9 has a very good μ and δ opioid receptor aﬃnity, showing 
comparable Ki values with respect to biphalin for MOR (Ki = 1.9 nM), DOR (Ki = 5.2nM), 
and KOR (Ki = 260 nM). Analogue 10 shows very low aﬃnity for all opioid receptors. 
Table 1. Binding affinity and in vitro bioactivity for compounds 9 and 10. 
comp 
Binding Affinity,a Ki (nM)
b 
δ µ κ 
Ctrlc 1.8 ± 0.5 1.0 ± 0.1 5.7 ± 0.5 
Bph 15 ± 2.3 2.6 ± 0.7 283.1 ± 182.3 
9 5.2 ± 0.5 1.9 ± 0.2 257.6 ± 25 
10 amb. amb. amb. 
a
 Displacement of [
3
H]Ile
5,6
deltorphin II (δ-ligand), [
3
H]DAMGO (μ-ligand) and [
3
H]U69593 (κ-ligand) from 
binding sites on rat brain membrane. 
b
 ± S.E.M. 
c
 The control was the appropriate opioid receptor 
specific ligand. amb.: ambiguous fitting, since the compound can inhibit specific receptor binding 
significantly only in the highest concentration. 
 
Isolated tissue based functional assays were also performed on guinea pig 
ileum/longitudinal muscle myenteric plexus (GPI) and mouse vas deferens (MVD) 
(Table 2).114,115,116 While compound 9 was potent in inhibiting muscle contraction both 
in MVD (expressing DOR) and in GPI (expressing MOR) assays, analogue 10 showed 
activity only in the micromolar range. These data are coherent with those obtained 
from the binding assays. The ability of 9 and 10 to stimulate the activation of G- 
proteins associated with the opioid receptors has been evaluated by [35S]GTPγS 
binding assay (Table 2-3 and Figure S2, Online Supporting Information1.2).117,118,119,120 
Analogue 9 has a similar μ and δ opioid receptor activation proﬁle as speciﬁc opioid 
ligands (DAMGO and Ile5,6 deltorphin II), unlike the κ opioid receptor. Furthermore, 
compound 9 has a signiﬁcantly higher eﬃcacy than biphalin in activating MOR. 
Interestingly, its eﬃcacy (Emax) on MOR is also higher than that of the cyclic Cys 
derivatives. 106,107,108 According to other in vitro assays, compound 10 shows a lower 
activity for all receptors. Overall in vitro results clearly suggest that D-residues in 
position 2,2′ are crucial for opioid receptor aﬃnity, which is in accordance with our 
previous SAR. 106,107,108 Thus, ligand 10, which possesses a disulﬁde bridge between L -
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penicillamines displays a remarkable loss of activity when compared to 9 and biphalin, 
displaying reduced binding aﬃnities for DOR and MOR, as well as for all the functional 
activities in the [35S]GTP γ S binding and the functional assays.  
Table 2. [
35
S]GTPγS binding (G-protein activation) assays. 
 δ receptor μ receptor κ receptor 
comp Emax (%)
a EC50 (nM)
b Emax (%)
a EC50 (nM)
b Emax (%)
a EC50 (nM)
b 
Ctrlc 142.6 ± 1.4 7.7 ± 1.9 465.2 ± 7.7 81 ± 12 202± 3.3 7.7 ± 1.8 
Bph 219.6 ± 5.7 90.5 ± 25 178.2 ± 3.6 12 ± 4.6 108.9 ± 4.1 amb. 
9 149.5 ±  2.3 7.1 ± 1.7 474.5 ± 4.1 76.2 ± 7.4 126.8 ± 4.4 480 ± 385 
10 142.6 ± 2.8 360 ± 121 162.2 ± 3.2 230 ± 82 124.5 ±  2.7 205.1 ± 137 
 
a
 Net total bound/basal binding x 100 ± S.E.M. 
b
 ± S.E.M. 
 
Table 3. [
35
S]GTPγS functional assays. 
comp 
Bioassay, IC50
d
 (nM)
b 
MVD (δ) GPI (μ) 
Ctrlc - - 
Bph 27 ± 15 e 8.8 ± 0.3 e 
9 7.2 ± 0.8  21 ± 4 
10 21% at 1 mM 4% at 1 mM 
c 
The control was the corresponding opioid receptor specific ligand (δ: Ile
5,6
deltorphine II; μ: DAMGO; κ: 
U69593). 
d
 Concentration at 50% inhibition of muscle contraction in electrically stimulated isolated 
tissues (n = 4). 
e
 Data according to Ref
.107,108,109
. amb.: ambiguous fitting, since the compound did not 
stimulate the receptor above basal activity significantly. 
 
Product 9 was also tested in vivo  for its antinociceptive activity. In the “ hot plate 
”and “tail ﬂick ” tests, analogue 9 produced about 95% of the MPE 15 min after i.c.v. 
administration. The maximum eﬀect was obtained 15–30 min after drug injection, and 
minimal decrease was observed for the next 30 min in both in vivo  models (Figure 2). 
Product 9 showed an activity several times higher than morphine after i.c.v. 
administration. Following i.v. administration (“hot plate” and “tail-ﬂick” tests), 
compound 9 displayed a greater and longer lasting antinociceptive eﬀect than biphalin, 
thus suggesting a likely improvement of the pharmacokinetic parameters if compared 
to biphalin, in accordance with the cyclization strategy.121,122 Also, the increased 
eﬃcacy of 9 at the MOR with respect to biphalin should play a role in this 
antinociceptive eﬀect. For detailed experimental procedures 123 , 124 and Online 
Supporting Information1.2. The bioactivity of 9 is still lower than morphine following 
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i.v. administration probably due to a reduced blood−brain barrier penetration of 9 
compared to morphine. 
 
Figure 2. Antinociceptive results, reported as maximum possible effect (MPE), of Hot Plate and Tail-Flick 
in vivo   bioassays for compound 9, biphalin and morphine sulphate. Compounds were injected i.c.v. 
(A&B) at a dose of 0.1 nmol/rat, and systemic i.v. administration (C&D) at a dose of 1500 nmol/Kg. The 
data represent the mean ± S.E.M. Statistical significance was assumed for P<0.05. *P<0.05 and 
***P<0.001 vs vehicle-treated animals; P<0.05 and °°P<0.01 vs biphalin-treated animals. N=8-10. 
 
To explain the activity di ﬀ erences between 9 and 10, a conformational analysis 
of the two analogues was carried out by solution NMR (Online Supporting 
Information1.2, Tables S1 − S5). Dodecylphosphocoline (DPC) micelle solution was used 
to mimic a membrane environment considering that opioid peptides interact with 
membrane receptors. 41,49 Using the NMR data as input, structure calculations by 
restrained simulated annealing gave the conformers shown in Figure 3. More details 
are reported in the Supporting Information. Both peptides 9 and 10 show a well-
deﬁned structure encompassing residues 1−4 (backbone root-mean-square deviation 
values are 0.27 and 0.21 Å, respectively). A γ –turn centered on Gly3 is seen in peptide 
9 (Figure 3A-B and Table S5, Online Supporting Information1.2). As expected from the 
NOE cross- peaks between the aromatic rings and the methyl groups of D-Pen2 (Figure 
S3, Online Supporting Information1.2), a sandwich-like π-CH3-π geometry of the signal 
sequence of the peptides was observed. Peptide 9 has similar activity proﬁle of the 
linear parent biphalin (MOR and DOR agonist) and diﬀerent from DPDPE, which 
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inspired the D-Pen−D-Pen bridge (selective DOR agonist).101 To explain peptide 9’s lack 
of μ/δ selectivity, we considered the distances between pharmacophoric points 
obtained by restrained molecular dynamics (Online Figure S4, Online Supporting 
Information1.2). Indeed, these distances are compatible with both μ and δ opioid 
receptors. 125,126 n fact, considering μ -selective peptides, the distances between the 
aromatic rings of Tyr1 and Phe4 should be in the range 10−13 Å,125 while the range 
characteristic for peptide and nonpeptide δ–selective compounds is about 7 Å. We 
found this distance ranging between 6 and 12 Å in peptide 9 (Online Figure S4C, 
Supporting Information) thus ﬁtting both the pharmacophores. In contrast, κ-receptor 
agonists require a shorter Tyr1 and Phe4 distance (about 5 Å) and a g− orientation of 
the Tyr1 side chain. 127 Those criteria are both unsatisﬁed by peptide 9. Finally, the 
inactivity of peptide 10 can be tentatively explained by a comparison of the peptide 
structures (Figure 3C). As observed, while the three pharmacophoric points (i.e., 
terminal amino group, center of the Tyr phenol, and center of the Phe phenyl ring) 
overlap very eﬃciently, the backbone atoms of residues 2−4 are not overlapping and 
the palindromic fragments (residues 1′−4′) point in opposite directions. Those non 
ﬁtting regions probably form incompatible interactions with the receptors in the case 
of peptide 10 thus accounting for its lack of activity. 
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Figure 3. Superposition of the ten lowest energy conformers of 9 (A), 10 (B). Structure models were 
superimposed using the backbone heavy atoms of residues 1-4. Heavy atoms have different colors 
(carbon: green, nitrogen: blue, oxygen: red, sulfur: yellow). Hydrogen atoms are hidden for a better 
view. (C) Superposition of peptides 9 (green) and 10 (yellow) using the three pharmacophoric points, i.e. 
terminal amino group (Nterm), center of the Tyr phenol (Y) and center of the Phe phenyl ring (F). 
 
CONCLUSIONS 
In conclusion, we have successfully developed two novel cyclic biphalin analogues. 
Compound 9, containing a D–Pen residue at position 2,2′, showed improved in vitro 
and in vivo activity compared to biphalin. According to previous SARs, compound 10, 
containing L-Pen, was virtually inactive. Conformational analysis pointed to a diﬀerent 
3D structure of the two analogues explaining their activity proﬁles. Further studies on 
the promising novel compound 9 using additional animal models are currently 
underway. 
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1.3 GRK2 INIHIBITORS 
INTRODUCTION 
The G protein-coupled receptor kinase family (GRKs) constitutes a group of seven 
protein kinases that specifically recognize and phosphorylate agonist-activated G 
protein coupled receptors (GPCRs) 128 . GRKs-mediated receptor phosphorylation 
triggers the binding of arrestin proteins that uncouple receptors from G proteins 
leading to rapid desensitization 129 , 130 , 131 . As a result of β-arrestin binding, 
phosphorylated receptors are also targeted for clathrin-mediated endocytosis, a 
process that classically serves to re-sensitize and recycle receptors back to the plasma 
membrane 132. In addition, both arrestins and GRKs participate in signal propagation, 
cooperating in the assembly of macromolecular complexes in the receptor 
environment and interacting with different components of signal transduction 128,133[. 
The seven mammalian GRKs family can be divided into three subfamilies based on 
sequence and functional similarity: visual GRK subfamily (GRK1 and GRK7), the β -
adrenergic receptor kinase (GRK2/ GRK3), and the GRK4 subfamily (GRK4, GRK5 and 
GRK6).128,134. All GRKs share a common topological structure that includes an N-
terminal regulator of G protein signalling homology domain (RH), a central kinase 
catalytic domain, and a C-terminal region containing a pleckstrin homology domain 
(PH).128,135 The best-characterized member of this family is the ubiquitously expressed 
GRK2, also known as β-adrenergic receptor  kinase 1 (β -ARK1).136 In the past 20 years, 
GRK2 emerges as a key node in signal transduction pathway playing a major role in the 
agonist-specific desensitization of several metabolism- -
adrenergic, melanocortin, endothelin, and glucose-dependent insulinotropic 
polypeptide receptors.136, 137 , 138 GRK2  can also phosphorylate other membrane 
receptors136, 139 as well as non receptor substrates136,138acting as effector in the 
regulation of diverse cellular functions from cardiovascular and immune cell 
functionality to migration and cell cycle progression. 136,140,141, 142,143 Furthermore, GRK2 
may also contribute to modulate cell responses in a phosphorylation-independent 
manner thank to its ability to interact with a plethora of proteins involved in signaling 
and trafficking.144 All these functional interactions predicts that alterations in GRK2 
Chapter 1 
 49  
 
levels and/or activity may have important effects in human disease,136,145 as those 
reported in several relevant cardiovascular, 146 , 147 , 148 , 149 , 150 , 151  inflammatory,152  or 
cancer pathologies.136,153 In particular, GRK2 plays a major role in the agonist-specific 
desensitization of β-adrenergic receptors (
transduction pathway of physiological relevance in the cardiovascular system 136,138,154. 
Alterations in GRK2 levels and/or activity may have important effects in several 
cardiovascular pathologies, such as myocardiac ischemia, hypertrophy, and 
hypertension, in which it is up regulated 155 , 156 , 157 , 158  In heart failure (HF), the 
relationship with increased cardiac GRK2 protein levels has been established in animal 
models and in patients 149,159,160,161,162. These data underline the importance of GRK2 
levels as a marker of predisposition to cardiac dysfunction 163,164 and support the idea 
that GRK2 offers a potential therapeutic target 136,165,166. In fact, the inhibition of GRK2 
activity by overexpression of GRK2ct (also termed β-ARKct), a construct that inhibits 
endogenous GRK2, has provided a successful approach for restoring cardiac function in 
mouse models with heart failure 167. Nevertheless, β-ARKct failed to deliver to the 
clinical scenario due to its dimension(≈ 200 aminoacids) and its need of genetic tools to 
express in the target tissue (adenovirus). Other inhibitors of GRK2 activity are currently 
available, even if they are characterized by low sensitivity and specificity 168,169,170,171. 
Strategies to selectively inhibit the GRK2 activity have been attempted using shorter 
peptides 172,173,174 or RNA aptamers 175. Myristyl or lauryl glycine derivatives of short 
peptides, such as KRX-683107 and KRX-683124 (Table 1), proved to be potent inhibitors 
of the kinase and possess hypoglycemic effect in animal models of Type 2 diabetes.174 
The peptide fragments of these compounds closely resemble the catalytic fragment 
383-390 KLLRGHSP of GRK2 (1). Several crystallographic and mutational studies, have 
pointed to HJ-αG residues as being involved in substrate binding and in binding to 
upstream activators.172,173 Based on these findings, this fragment and, more concretely, 
compounds 2 and 3 appeared to be valuable starting points for the development of 
novel specific and more potent GRK2 inhibitors(Table 1).  
First, by Ala-scan analysis and conformational study by NMR we described the 
structure-activity relationship (SAR) of peptides 2 and 3.  
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Furthermore, these compounds 2 and 3 were valuable starting points for the 
development of novel cyclic peptides GRK2 inhibitors. In fact, conformational analysis 
of peptides 2 and 3 clearly indicated that their structures are very similar to the X-ray 
structure of the fragment encompassing the HJ loop of the GRK2, indicating that the 
isolated peptide could keep the 3D structure of the protein segment. Based on these 
results, we designed, synthesized, and evaluated the GRK2 inhibitor activities of a 
small libraries of cyclic peptides. In addition, we discussed the biological effects of 
GRK2 inhibition on β adrenergic receptor signaling for the most potent derivative 
characterized in this work. 
Table 1. Different peptide fragments considered in this study. 
Name  Sequences 
KRX-683107 Myristyl G L L R r H S  
KRX-683124 Lauryl G L L R r H S I 
383-390HJ loop (1)  K L L R G H S P 
2  G L L R r H S  
3  G L L R r H S I 
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1.3.1 SAR study and conformational analysis of novel peptides 
GRK2 inhibitors 
 
RESULTS 
Synthesis and biological activity. In a first classical approach, a series of L-Ala-
substituted analogues of peptides 2and 3, were synthesized in order to evaluate the 
amino acid side chains involved in the interaction with the target molecule (4-16, Table 
2). To verify the effect of chirality, the D-Arg at position 5 was also replaced by D-Ala 
(17 and 18). Peptides 2-18 were synthesized by standard 9-fluorenylmethoxy carbonyl 
(Fmoc) chemistry using an appropriate orthogonal protection strategy.176  
The effectiveness of these peptides to inhibit GRK2 kinase activity was assessed by in 
vitro assay using GRK2 purified protein and the G protein–coupled receptor rod outer 
segments (ROS) as a substrate (Table 2) in presence of [γ-32P]-adenosine triphosphate 
(ATP). Peptide 2 causes a 47.6±5.5% inhibition of GRK2 activity on ROS; within the 
sequence of 2, the amino acids Leu2, Leu3, and D-Arg5 are relevant for the inhibitory 
properties of the reference peptide. Also C-terminal residues proved to be important, 
since Ala replacement of His6 and Ser7 led to about three and two-fold reduction of 
the inhibitory activity. As in the original sequence the amino acid in position 5 is a D-
enantiomer (D-Arg), we also substitute this amino acid with a D-Ala (peptide 17) in 
order to discern the real role of molecular orientation from the effects of the amino 
acid side chain on the inhibitory activity. We found that indeed, substitution with a 
neutral D amino acid such as alanine maintained the inhibitory properties of the 
resulting peptide 17 (55.5±4.7%). 
A similar approach was assessed for peptide 3. First of all, 3 causes a 49.6±6.3% 
decrease in  GRK2 activity. Ala substitution in position Leu2, Leu3 and Arg4 (peptides 
10, 11, and 12) does not change the inhibitory property of the parent peptide 2. On the 
contrary, changes of residues D-Arg5, His6, Ser7, and Ile8 lead to compounds (13, 14, 
15, and 16) that are devoid of inhibitory activity. Similarly to peptide 2, the 
reinstallation of D- chirality in residue 5 restores the inhibitory properties of resulting 
peptide 18 on GRK2 (63.2±9.7%) which showed the highest GRK2 inhibition potency of 
the series.  
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To test the specificity of the peptides for GRK2 rather than for the substrate, we also 
repeated the same experiment using as substrate Myelin Basic Protein (MBP). With 
this substrate, we observed a similar inhibition pattern as for ROS (Table 2).  
Next, to verify whether these peptides selectively inhibit GRK2, we repeated the 
activity assay substituting GRK5 to GRK2 purified protein. GRK2 selective inhibition is 
suggested by the evidence that all peptides don’t affect GRK5 kinase activity on 
rhodopsin or  MBP phosphorylation levels (Table 2). 
Table 2. Structure, inhibition activities, and analytical data of linear peptides 1-17 
Peptide Sequence 
Inhibition (%±SD)a 
ROSb MBPc 
2 GLLRrHS 47.6±5.5 54.2±6.1 
4  GALRrHS <5 <5 
5 GLARrHS <5 <5 
6  GLLArHS 42.2±9.7 38.2±4.5 
7  GLLRAHS <5 <5 
8  GLLRrAS 13.5±6.4 25.6±5.7 
9  GLLRrHA 22.3±5.4 28.8±9.2 
3 GLLRrHSI 49.6±6.3 60.2±5.0 
10  GALRrHSI 45.7±12.3 54.5±9.1 
11  GLARrHSI 46.6±12.3 47.7±7.2 
12  GLLArHSI 45.7±6.2 42.1±7.8 
13  GLLRAHSI <5 <5 
14  GLLRrASI <5 <5 
15  GLLRrHAI <5 <5 
16  GLLRrHSA <5 <5 
17  GLLRaHS 55.5±4.7 54.2±3.2 
18 GLLRaHSI 63.2±9.7 55.5±6.0 
 
a
Data represent mean values (±SD) of three independent determinations.
 b
GRK2 purified protein activity 
(50 ng) was tested on rod outer segments (ROS) in presence or absence of 1μM inhibitors. 
c 
GRK2 
purified protein activity (50 ng) was tested on Myelin Basic Protein (MBP) in presence or absence of  
1μM inhibitors.  
 
To verify the effectiveness of GRK2 inhibition in a cellular contest, we tested the 
effects of GRK2 inhibitors in cells on the cyclic adenosine monophosphate (cAMP) 
production. In Hek293 cells stably overexpressing the β2 adrenergic receptor (β2AR),
139 
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incubation with compounds 2, 3, and 18 resulted in a slight increment of basal and βAR 
stimulated cAMP production in HEK-293 cells (Figure 1). Interestingly, the lead 
compound 2 results to be the most effective in this assay. 
 
Figure 1. cAMP production in HEK-293 cells treated with 2, 3 and 18 as determines by enzyme 
immunoassay. ISO: Isoproterenol. Each data point represents the mean±SEM of 3 independent 
experiments; * =  p<0.0001 vs  Ctr; # = p<0.01  vs Iso. 
 
NMR Analysis of selected peptides. NMR analysis of peptides 2, 3, 17, and 18 was 
performed in water and dodecylphosphocholine (DPC)  micelle solutions. Almost 
complete 1H NMR chemical shift assignments (Online Supporting Information 1.3.1, 
Tables S1-S8) were achieved according to the Wüthrich procedure.31 Considering the 
spectra in water solution, all NMR parameters indicated structural flexibility (Online 
Supporting Information 1.3.1, Tables S1-S4). For example, no standard α-helix or β-
sheet structure from Hα CSI (chemical shift index) values,
62,177and no unambiguous 
medium- or long-range backbone NOE connectivities were found in the NOESY 
spectrum of the peptides. Only strong dαN(i, i+1) NOEs, which are generally observed in 
random structures, appeared along the entire length of the peptides. In contrast, 
several NMR parameters indicate that peptides are better structured in 
dodecylphosphocholine (DPC) solution and that they share very similar conformations. 
In particular, Hα resonances (Online Supporting Information 1.3.1, Tables S5-S8), and 
many NOE signals clearly point to a folded structure encompassing the N-terminal 
residues (1-5) and extended conformation of residues 6-8 (6-7 for 2 and 17). Non-
trivial medium range NOE interactions, among which dαN(i, i+2) 1-3, 2-4, 3-5, dNN(i, i+2) 
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2-4, and dαN(i, i+3) 1-4, are observed pointing to a turn-helical structure along residues 
1-5. Low temperature coefficient of the backbone amide proton of residue 4 (-Δδ/ΔT ~ 
4 ppb/K) confirms this hypothesis. C-terminal region is in extended conformation as 
indicated by the strong dαN(i, i+1) NOEs and large 
3JHN-Hα coupling constants. Finally, 
NOE contacts between Arg4 and His6 side chains indicate that these are spatially close. 
NOE distance restraints obtained for peptide 18 in DPC micelles (Online 
Supporting Information 1.3.1, Table S9) were used as the input data for a simulated 
annealing structure calculation using the program DYANA.178 Superposition of the 10 
lowest energy conformers of 18 is shown in Figure 2. The root mean square deviation 
(RMSD) to the average structure for backbone heavy atoms is 0.31 Å. Since a β-turn 
may be defined as four consecutive non-helical residues that have a Cα(i)-Cα(i+3) 
distance < 7 Å, two β -turns that involve Gly1 to Arg4 and Leu2 to D-Ala5, can be 
identified.  
The first β-turn structure is stabilized by a hydrogen bond between the 
carbonyl oxygen of Gly1 and the amide hydrogen of Arg4. Residues 6 and 7 are in 
extended conformations, residue 8 is more flexible. The side chain are also well 
defined, the RMSD for all heavy atoms is 0.74 Å. The side chains of Arg4 and His6 are 
close and form a positively charged hydrophilic surface while Leu2 and Leu3 side chains 
establish a hydrophobic surface pointing in the opposite direction. Interestingly, the 
sequential dαN(i, i+1) NOEs between Leu
2-Leu3, and Leu3-Arg4 indicative of 
extended/random conformations are consistently violated by the turn structures 
(violations of about 0.20 Å). It can be hypothesized the existence of a conformational 
equilibrium between the turns and less defined structures for these peptides. 
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Figure 2. Stereoview of the 10 lowest energy conformers of 18. Structures were superimposed using the 
backbone heavy atoms. Heavy atoms are shown with different colours (carbon, green; nitrogen, blue; 
oxygen, red). Hydrogen atoms are not shown for clarity. 
DISCUSSION 
In the present study, we performed a SAR study and a NMR conformational analysis 
of peptides 2 and 3 which are able to selectively inhibit GRK2.174 Ala-scan results (Table 
2) indicated that, while C-terminal residues are important for the activity of both 
peptides, N-terminal residues Leu2 and Leu3 are important only for the shorter peptide 
2. Since the conformational preferences in solution of the two peptides are very 
similar, a possible explanation of the different SAR observed is that hydrophobic 
interaction of residues Leu2 and Leu3 with the target are borrowed by Ile8 in peptide 3 
(Ile8 is lacking in peptide 2). Arg4 side chain is of little importance for the activity of 
both the peptides, in contrast, replacement of Arg5 with Ala completely abolishes the 
inhibitory activity. Since in the original sequence, the amino acid in position 5 is a D-
enantiomer, D-Arg5 was substituted by D-Ala, in order to discern the real role of 
molecular orientation from the effects of the amino acid side chain on the inhibitory 
activity. We found that substitution with a neutral D amino acid such as alanine does 
not change the inhibitory properties of the peptides 2 and 3, thus suggesting an 
important role for the chirality of aminoacid 5 rather than for the side chain. 
Interestingly, both side chains of Arg4 and D-Arg5 can be replaced by a neutral amino 
Chapter 1 
 56  
 
acid when the chirality is retained. Indeed, peptide 18 (D-Ala derivative of peptide 3) 
showed the highest GRK2 inhibition potency of the series. These peptides retain 
specificity for the GRK2 since they were equally effective on GRK2 using two different 
substrates. Also, they keep selectivity since they are ineffective in inhibition GRK5 
activity on the same substrates.  
Peptide 2, 3, 18 ability to increment basal and βAR stimulated cAMP production in 
HEK-293 cells is consistent with their effective inhibition of GRK2 (Figure 1). However, 
the low entity of those increments is likely due to the difficulty of the peptides to cross 
the cell membrane. The slight higher activity of peptide 3 compared to 2 roughly 
parallels its higher GRK2 inhibition potency. Differently, slight higher activity of peptide 
3 compared to 18 would indicate that, even if D-Arg5 is dispensable for GRK2 
interaction (Table 2), it can improve the permeating properties of the peptide. NMR 
analysis of peptides 2, 3, 17, and 18 was performed in water and DPC micelle solutions. 
The last is a membrane mimetic medium and was chosen since GRK2 phosphorylation 
of GPCRs occurs close to the plasma membrane. Peptides conformational preferences 
are similar since they have similar diagnostic NMR parameters. Peptides structures in 
DPC micelles are characterized by two β-turns that involve Gly1 to Arg4 and Leu2 to D-
Ala5 (or D-Arg5), followed by a short extended region encompassing residues 6 and 7 
(Figure 2). The NMR structures of the peptides in DPC are very similar to the X-ray 
structure of the fragment encompassing the HJ loop of the GRK2 (pdb entry 
3CIK)179which, indeed, was the starting point for the design of the peptides 12 and 3.174 
Figure 3 shows the superposition of the NMR structure of 18 with that of the fragment 
383-390 of the GRK2. Equivalent backbone atoms of 18 and GRK2 superimpose to an 
RMSD of 1.00 Å. It can be also observed the good overlapping of the unchanged side 
chains which occupies similar space regions. Therefore, the isolated peptide keeps the 
3D structure of the protein segment and likely competes with the activation functions 
of this loop.172, 173 
This result could explainthe selectivity observed for these peptides toward GRK2 
compared to GRK5. In fact, GRK5 HJ loop corresponding sequence is MIEGQS (CLUSTAL 
Omega alignment; www.e-bi.ac.uk/Tools/msa/clustalo) which compared to the GRK2 
sequence LLRGHS has, inter alia, a very different chargecontent (-1 vs. +1/+2) 
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Figure 3. Stereoview of 18 lowest energy conformer (green) and fragment 383-390 of GRK2 (yellow, pdb 
entry 3CIK). The structures are superimposed using the backbone heavy atoms. Structure orientation is 
the same as in Figure 2. 
CONCLUSIONS 
GRK2 is involved in the regulation of many pivotal cell functions, and is therefore a key 
player in human health and disease, such as in determinate pathological cardiovascular 
processes as heart failure. Hence, modulation of its activity could be exploited with 
therapeutic purposes. The present study describes the synthesis, SAR study and 
conformational analysis of two HJ-loop derived peptides which are able to selectively 
inhibit GRK2. Starting from peptides 2 and 3, previously described, this study: i) found 
the (in)dispensable residues which can be replaced in an attempt to improve peptide 
properties (GRK2 interaction, membrane permeation); ii) determined their 
conformational preferences which can help the design of novel peptides and peptido-
mimetics with enhanced conformational stability.  
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1.3.2 Design, synthesis and efficacy of novel cyclic peptides 
GRK2 inhibitors 
RESULTS 
Design. As stated above (see 1.3.1), peptides 2 and 3 selectively inhibit GRK2 in vitro. 
Their NMR solution conformations are very similar to the crystal structure of the 
fragment encompassing the HJ loop of the GRK2 (pdb entry 3CIK, Figure 1). 179 Hence, 
it can be hypothesized that the active conformation of the peptides resemble the HJ 
loop crystal structure. Accordingly, the stabilization of the peptide 3D structure by, for 
example, the cyclization of these linear compounds can be considered as a valid 
approach to the identification of more potent, (stable and selective) compounds. As 
evident from Figure 1, N- and C-terminal sides of the loop fragment are relatively close 
(~5 Å), hence we first carried out a head-to-tail cyclization of peptides 2 and 3 leading 
to peptides 4 and 5, respectively (Table 2).  
The design of a second group of cyclic peptides is based on the consideration that, in 
the GRK2 crystal structure, the amino group of K383 side chain points towards the 
Ser389 side chain (Figure 1). Hence, the stabilization of the peptide structure was also 
sought through a side chain-to-side chain cyclization approach. The cyclic peptides 6 
and 7 (Table 2) were synthesized from linear peptides which contain the original 
residue Lys383 of GRK2 instead of Gly1 and an Asp residue in place of Ser7 residue. 
These two residues are linked by a side chain amide bond. For comparative purpose 
the analogues 8 and 9, containing the original Gly387 residue at the position 5, were 
also synthesized and tested for their activity to inhibit GRK2. 
 
Figure 1. Stereoview of the crystal structure of the fragment 383-390 of GRK2 (1, pdb entry 3CIK). Heavy 
atoms are shown with different colours (carbon, green; nitrogen, blue; oxygen, red). Hydrogen atoms 
are not shown for clarity. Cyclization strategies are shown as dotted lines.  
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Synthesis. Head-to-tail cyclic peptides (4 and 5) were prepared on acid-labile 2Cl-Trt 
resin by solid-phase synthesis of linear peptide sequences, using the Fmoc protection 
strategy, followed by cyclization and side-chain deprotection in solution. 176 The 
preparation of cyclic peptides, 6-9, through a side-chain-to-side-chain cyclization, was 
carried out after removal of the Allyl/Alloc protection according to strategy reported  
by Grieco et al. 180  
Table 2. Structure, inhibition activities, and analytical data of peptides 2-9. 
Com. Sequence 
Inhibitiona 
 
HPLCc  ESI-MS (M+H) 
GRK2b GRK5 k’ Calcd Found 
2d GLLRrHS 47.6±5.5 < 5 1.70 836.97 837.66 
3d GLLRrHSI 49.6±6.3 < 5 1.72 950.13 950.70 
4 [GLLRrHS] 47.8±6.0 < 5 1.70 819.96 820.53 
5 [GLLRrHSI] 37.2±10.7 < 5 1.85 933.12 933.80 
6 [KLLRrHD] 36.3±4.4 < 5 1.72 919.09 920.13 
7 [KLLRrHD]I 55.3±4.6 < 5 1.75 1032.25 1033.11 
8 [KLLRGHD] 47.2±4.5 < 5 1.76 819.47 820.51 
9 [KLLRGHD]I 33.7±7.8 < 5 1.78 933.12 933.68 
a
Data represent mean values (±SD) of three independent determinations.
 b
GRK2 and GRK5 purified 
inhibitors. 
c
k’=[(peptide retention time solvent retention time)/ solvent retention time]. 
d
Already 
reported in reference
139
 
 
Biological activity. The effectiveness of these peptides to inhibit the GRK2 kinase 
activity  was assessed by in vitro rhodopsin phosphorylation assay and visualized by 
autoradiography of dried gels (Figure S1, Online Supporting Information 1.3.2). 
Peptides with cyclic modifications retain the ability to inhibit GRK2, although in some 
cases (such as peptides 5, 6 and 9) they lose some efficacy compared to the original 
peptides (Table 2). In particular, C-terminal Ile residue caused different effects 
depending on the peptide structure. In fact, in linear peptides the inhibitory activity 
was not affected by the C-terminal Ile (peptide 2 vs. peptide 3). In cyclic peptides, C-
terminal Ile can both increase (peptide 6 vs. peptide 7) and decrease (peptide 4 vs. 
peptide 5 and peptide 8 vs. peptide 9) the inhibitory activity. Overall, lactam cyclic 
peptide 7 is the most active to inhibit GRK2 gaining about 10% of activity compared to 
the parent peptide 3. In addition, the dose response curves for the most potent 
compounds 3 and 7, at concentration range from 10-3 to 10-9M, conﬁrm the ability of 
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these compounds to inhibit GRK2-mediated ROS phosphorylation in dose-dependent 
manner (Figure S2, Online Supporting Information 1.3.2). Calculated IC50’s were 3.4±0.3 
10-7M (peptide 3) and 1.2±0.6 10-7M (peptide 7) conﬁrming a slightly higher potency of 
the latter. Next, to verify whether these peptides selectively inhibit GRK2, we repeated 
the activity assay substituting GRK5 to GRK2 puriﬁed protein (Table 2). GRK2 selective 
inhibition is suggested by the evidence that all peptides don’t affect GRK5 kinase 
activity on rhodopsin phosphorylation levels. To conﬁrm the effectiveness of GRK2 
inhibition in a cellular setup, we tested the effects of GRK2 inhibitors in cells on beta 
adrenergic receptors density in HEK-293 cells stably over-expressing the β2 adrenergic 
receptor ( β2AR).
139 In HEK-293 cells, incubation with compound 3 or the cyclic peptide 
7 (1μM) results in the increase in β2AR density, consistent with an effective inhibition 
of GRK2 (Figure 2A). Accordingly, basal and βAR stimulated cAMP production in HEK-
293 cells was signiﬁcantly affected by peptide 7 (Figure 2B). Interestingly, peptide 7 
results to be more effective than the lead compound 3 in both assays. 
 
Figure 2. A) β2-adrenergic receptors density in HEK-293 cells treated with peptides 3 and 7 (1 µM for 1 
h). Each data point represents the mean±SEM of 3 independent experiments; * p-value ≤ 0.05. B) cAMP 
production in HEK-293 cells treated with 3 and 7 as determined by cAMP immunoassay. ISO: 
Isoproterenol, 0.1 µM. Each data point represents the mean±SEM of 3 independent experiments; ** 
p<0.0001 vs Ctr; # p<0.01 vs ISO. 
 
Previous experiments on intact cells indicate that peptides 3 and 7 are able to 
penetrate cell membrane. To demonstrate this point, we measured the internalization 
of both fluorescently labelled peptides (Fl-3 and Fl-7, respectively). As observed in 
Figure 3A and B, both peptides are able to cross cell membrane with the linear 
compound Fl-3 incorporated to cells more effectively than compound Fl-7.  
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Figure 3. A) Incorporation of fluorescently labelled peptides into β2HEK-293 cells. The cells were 
incubated with 1 μM Fl-3 (upper panel) and Fl-7 (lower panel) for 1 h. Images were obtained by confocal 
microscopy. B) Quantification of 3 experiments measuring fluorescence incorporation of the cells 
incubated with either Fl-3 or Fl-7, at either 10 μM or 1 μM. p<0.01 vs Control (Ctr). 
 
NMR Analysis of cyclic peptide 7.  NMR analysis of peptide 7 was performed in 
water and DPC micelle solutions. Almost complete 1H NMR chemical shift assignments 
(Online Supporting Information 1.3.2, Tables S1-S2) were achieved according to the 
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Wüthrich procedure.31. Considering the spectra in water solution, all NMR parameters 
indicated structural flexibility (Online Supporting Information 1.3.2, Table S1). For 
example, no standard α-helix or β-sheet structure from Hα CSI (chemical shift index) 
values177, and no unambiguous medium- or long-range backbone NOE connectivities 
were found in the NOESY spectrum of the peptides. Only strong dαN(i, i+1) NOEs, which 
are generally observed in random structures, appeared along the entire length of the 
peptides. In contrast, several NMR parameters indicate that peptides are better 
structured in DPC solution and that they share very similar conformations. In 
particular, Hα resonances (Online Supporting Information 1.3.2, Table S2), and many 
NOE signals (Online Supporting Information 1.3.2, Table S3) clearly point to a folded 
structure encompassing the N-terminal residues (1-5) and extended conformation of 
residues 6-8. Non-trivial medium range NOE interactions, among which dαN(i, i+2) 1-3, 
2-4, 3-5, dNN(i, i+2) 2-4, and dαN(i, i+3) 1-4, are observed pointing to a turn-helical 
structure along residues 1-5. Low temperature coefficient of the backbone amide 
proton of residue 4 (-Δδ/ΔT ~ 4 ppb/K) confirms this hypothesis. C-terminal region is in 
extended conformation as indicated by the strong dαN(i, i+1) NOEs and large 
3JHN-Hα 
coupling constants. Finally, NOE contacts between Arg4 and His6 side chains indicate 
that these are spatially close.  
NOE distance restraints obtained for peptide 7 in DPC micelles were used as the 
input data for a simulated annealing structure calculation using the program DYANA. 
178 Superposition of the 10 lowest energy conformers of 7 is shown in Figure 4. The 
mean RMSD to the average structure for backbone heavy atoms is 0.20 Å. Since a β-
turn may be defined as four consecutive non-helical residues that have a Cα (i)-Cα (i+3) 
distance < 7 Å, two β-turns that involve Gly1 to Arg4 and Leu2 to D-Ala5, can be 
identified.  
The first β-turn structure is stabilized by a hydrogen bond between the carbonyl 
oxygen of Lys1 and the amide hydrogen of Arg4. Residues 6 and 7 are in extended 
conformations, residue 8 is more flexible. The side chain are also well defined, the 
RMSD for all heavy atoms is 0.74 Å. The side chains of Arg4 and His6 are close and form 
a positively charged hydrophilic surface while Leu2 and Leu3 side chains establish a 
hydrophobic surface pointing in the opposite direction.  
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Figure 4. Stereoview of the 10 lowest energy conformers of 7. Structures were superimposed using the 
backbone heavy atoms. Heavy atoms are shown with different colours (carbon, green; nitrogen, blue; 
oxygen, red). Hydrogen atoms are not shown for clarity. 
 
DISCUSSION 
The aim of the present study was the design of new analogues of peptides 2, and 3, 
potent and selective inhibitors of GRK2. (See 1.3.1) Peptides 2 and 3 are the not 
acylated derivatives of compounds KRX-683107 and KRX-683124, respectively (Table 1), 
in turn derived from the fragment 383-390 of the HJ loop of GRK2 (1, Table 1). 
Conformational similarity of these peptide to the protein fragment within the crystal 
structure of GRK2179, prompted us to design novel analogues of peptides 2 and 3 based 
on head-to-tail and side chain-to-side chain cyclization, according to the HJ loop 
structure (Figure 1). Hence, the lactam were introduced as a conformational constraint 
to stabilize the putative 3D active conformation. The utility of backbone or side chain 
cyclization has been well established in peptides, and it has been demonstrated to 
increase biological activity and selectivity since they are usually more stable in 
metabolism than the parent linear molecules.181 In this context, lactam bridges are 
preferable over disulfide ones due to their chemical stability.182 
All cyclic peptides retain the ability to inhibit GRK2 (Table 2) demonstrating the 
validity of the design strategy. Potency fluctuations were observed upon the insertion 
of Ile8 in cyclic analogues. Probably, conformational restraints imposed by the 
cyclization also affect exocyclic Ile residue spatial orientation which, in turn, influences 
the inhibitory activity. Cyclic peptide 7 is the most active in the GRK2 inhibition 
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overcoming of about 10% its precursor (peptide 3). Interestingly, peptides also retain 
selectivity towards GRK2 since they don’t affect GRK5 kinase activity on rhodopsin 
levels. To bring our observation to a biological setup, we tested the effects of GRK2 
inhibitors in cells on the beta adrenergic receptors density. Indeed, it is known that 
GRK2 inhibition can change the affinity state of the beta adrenergic receptor by 
preventing desensitization 183, furthermore recent evidences suggest that also the total 
number of β adrenergic receptors is under the control of GRK2 activity184, thus 
indicating that the kinase also control downregulation, the major and most effective 
mechanism of regulation of βAR signaling. Interestingly, peptide 7 results to be more 
effective than the lead compound 3 to increase β2AR density (Figure 2A). Similar 
results are obtained in cAMP production studies. In fact, 7 increases both basal and 
β2AR stimulated cAMP production in cells (Figure 2B). These results are particularly 
important since they indicated these peptides are able to penetrate the cell membrane 
by itself without the need of acylation (as for KRX-683124), conjugation with cell 
penetrating peptides, etc. To confirm this important suggestion, we measured the 
internalization of both fluorescently labelled peptides (Fl-3 and Fl-7, respectively). As 
observed in Figure 3A and B, both peptides cross cell membrane in an effective 
manner. Probably, peptide 7 highest potency in the inhibition of GRK2 kinase activity is 
the predominant factor determining the observed significant increase of β2 adrenergic 
receptor density and cAMP production.  
Promising compound 7 was also investigated for its conformational preferences. 
NMR analysis of peptide 7 was performed in water and DPC micelle solutions. It is well-
known that water is the best medium to be used for the structural study of peptides. 
Unfortunately it favors the prevailing of disordered and flexible conformations so that 
the building of a 3D model is often precluded. Mixtures made up of water and organic 
solvents are the most used media to produce environmental constraints. In particular, 
alcohols and fluoro alcohols are known to stabilize peptide secondary structures 185. 
Micelle solutions are membrane mimetic environments and are largely used for 
conformational studies of peptide hormones and antimicrobial peptides 186. In this 
case, a micellar solution of DPC was chosen since GRK2 phosphorylation of GPCRs 
occurs close to the plasma membrane. Peptide 7 structure in DPC micelles is 
characterized by two β-turns that involve Gly1 to Arg4 and Leu2 to D-Arg5, followed by 
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a short extended region encompassing residues 6 and 7 (Figure 5). Compared to the 
linear parent peptides (see 1.3.1), compound 7 shows a lower conformational 
flexibility (in fact, the backbone heavy atoms RMSD decreases from 0.31 to 0.20 Å, 
compared to the linear analogue). 
More interestingly, the NMR structures of peptide 7 is very similar to the crystal 
structure of the fragment encompassing the HJ loop of the GRK2 (pdb entry 3CIK).179 
Figure 5 shows the superposition of the NMR structure of 7 with that of the fragment 
383-390 of the GRK2. Equivalent backbone atoms of 7 and GRK2 superimpose to an 
RMSD of 0.17 Å. It can be also observed the good overlapping of the unchanged side 
chains which occupies similar space regions. Also, Ile8 side chain is well overlapped 
with that of Pro390, supporting the positive contribution of this residue on peptide 
activity. Therefore, the isolated peptide keeps the 3D structure of the protein segment 
and likely competes with the activation functions of this loop.172,173 
 
Figure 5. Stereoview of 7 lowest energy conformer (green) and fragment 383-390 of GRK2 (1, yellow, 
pdb entry 3CIK). The structures are superimposed using the backbone heavy atoms. 
 
CONCLUSIONS 
GRK2 is involved in the regulation of many pivotal cell functions, and is therefore a 
key player in human health and disease, such as in determinate pathological 
cardiovascular processes as heart failure. Hence, modulation of its activity could be 
exploited with therapeutic purposes. The present study describes the design, 
synthesis, and biological evaluation of a series of cyclic peptides which are able to 
selectively inhibit GRK2. In particular, cyclic peptide 7 demonstrated to increase the 
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inhibitory potency of the linear parent 3. Our results showed that 7 also increased, 
more effectively than 3, the density of β adrenergic receptors and the βAR stimulated 
cAMP production in cardiac cells, further confirming the GRK2 control on regulation of 
βAR signalling. These findings confirm that conformational-based chemical 
modification of the linear fragment encompassing the HJ loop of the GRK2 is an 
effective approach to identify structures able to modulate GRK2 activity through 
inhibition. Further in vivo  experiments aimed to verify the potentiality of this peptide 
in the cardiovascular system as well as the preparation of novel more potent and 
selective peptide and peptidomimetic derivatives are in progress. 
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EXPERIMENTAL SECTION 
CHEMISTRY 
Synthesis of hU-II analogues. Nα-Fmoc-protected amino acids, HBTU and 
HOBt were purchased from Inbios (Naples, Italy). Wang resin was purchased from 
Advanced ChemTech (Louisville, KY). Protected Pen was purchased from Bachem 
(Basel, Switzerland). Peptide synthesis solvents, reagents, as well as CH3CN for HPLC 
were reagent grade and were acquired from commercial sources and used without 
further purification unless otherwise noted. All synthesized compounds showed a 
purity >98% as determined by analytical RP-HPLC. 
The synthesis of hU-II analogues was performed in a stepwise fashion via the solid-
phase method.42 The first amino acid Nα-Fmoc-Val-OH was coupled to Wang resin (0.5 
g, 0.7 mmol NH2/g) in presence of DMAP.
43 The following protected amino acids were 
then added stepwise: 
 Nα-Fmoc-Cys(Trt)-OH, Nα-Fmoc-Tyr(OtBu)-OH, Nα-Fmoc-Yaa(Nɛ-Boc)-OH (Yaa: 
Lys, Orn), Nα-Fmoc-Xaa(Nin-Boc)-OH (Xaa: Tpi, D-Tpi), Nα-Fmoc-Phe-OH, Nα-
Fmoc-Pen(Trt)-OH and Nα-Fmoc-Asp(Trt)-OH; for the Trp7-Costrained 
analogues of P5U and Urantide (See 1.1.1). 
 Nα-Fmoc-Cys(Trt)-OH, Nα-Fmoc-Tyr(tBu)-OH, Nα-Fmoc-Orn(N-Boc)-OH, Nα-
Fmoc-DTrp(Nin-Boc)-OH, Nα-Fmoc-Phe-OH, Nα-Fmoc-Cys(Trt)-OH and Nα-Fmoc-
Ala-OH; for the URP peptide.;for Urantide (See 1.1.2). 
 Nα-Fmoc-Cys(Trt)-OH, Nα-Fmoc-R-OH, [R = Nal(1), Nal(2), Btz, (pCl)Phe, (3,4-
Cl)Phe, (pCN)Phe, (pNO2)Phe], N
α-Fmoc-Yaa(Nɛ/δ-Boc)-OH (Yaa: Lys, Orn), Nα-
Fmoc-Xaa(Nin-Boc)-OH (Xaa: Trp, DTrp), Nα-Fmoc-Phe-OH, Nα-Fmoc-Pen(Trt)-
OH and Nα-Fmoc-Asp(OtBu)-OH; for the Tyr9 modified analogues of P5U and 
Urantide (See 1.1.3). 
 Nα-Fmoc-Cys(Trt)-OH, Nα-Fmoc-Tyr(tBu)-OH, Nα-Fmoc-Lys(N-Boc)-OH, Nα-
Fmoc-Trp(Nin-Boc)-OH, Nα-Fmoc-Phe-OH, Nα-Fmoc-Cys(Trt)-OH and Nα-Fmoc-
Ala-OH; for the URP peptide (See 1.1.4). 
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Each coupling reaction was accomplished using a 3-fold excess of amino acid with 
HBTU and HOBt in the presence of DIEA. The Nα-Fmoc protecting groups were 
removed by treating the protected peptide resin with a 25% solution of piperidine in 
DMF, (1x5 min and 1x20 min). The peptide resin was washed three times with DMF 
and the next coupling step was initiated in a stepwise manner. All reactions were 
performed under an Ar atmosphere. The peptide resin was washed with DCM (3x), 
DMF (3x) and DCM (4x), and the deprotection protocol was repeated after each 
coupling step. The N-terminal Fmoc group was removed as described above and the 
peptide was released from the resin with TFA/Et3SiH/H2O 90:5:5 for 3 h. The resin was 
removed by filtration and the crude peptide was recovered by precipitation with cold 
anhydrous ethyl ether to give a white powder which was purified by RP-HPLC on a 
semi-preparative C18-bonded silica column (Phenomenex, Jupiter 4μ Proteo 90Å, 1.0 x 
25 cm) using a gradient of CH3CN in 0.1% aqueous TFA (from 10 to 90% in 40 min) at a 
flow rate of 5.0 mL/min. The product was obtained by lyophilization of the appropriate 
fractions after removal of the CH3CN by rotary evaporation. Analytical RP-HPLC 
indicated for all synthesized compounds a purity >98% and the correct molecular 
weights were confirmed by LC/ESI-MS (6110 Quadrupole, Agilent Technologies). The 
quantitative amino acid analysis was performed using an Applied Biosystems model 
420A (Table A and B, Supporting Information). 
General Method of Oxidation and Cyclization. The peptides were oxidized by the 
syringe pump method previously reported.187 The linear peptide (300-500 mg) was 
dissolved in 40ml of H2O/acetonitrile/methanol 2:1:1, and nitrogen gas was passed 
through the solution for 20 min. Five milliliters of saturated ammonium acetate 
solution were added, and the pH was taken to 8,5 with NH4OH. The peptide solution 
was then added at room temperature via syringe pump to a stirred oxidant solution. 
The oxidant solution was prepared as follows: 2 equiv of potassium ferricyanide were 
dissolved in 800 ml of H2O/acetonitrile/methanol 2:1:1. To this solution was added 100 
ml of saturated ammonium acetate, and the pH was then taken to 8.5 with NH4OH. 
The peptide solution was added at such a rate that approximately 10 mg of peptide 
were delivered per hour per liter of the oxidant. After the addition of peptide was 
complete, the reaction mixture was stirred for an additional 5-6 h and then taken to 
pH 3.5 with glacial acetic acid. Amberlite IRA-68 (Cl - form) was added to remove the 
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iron ions and the solution stirred for 20 min and then filtered. The solution was 
concentrated using a rotary evaporator at 30°C and then lyophilized. The material thus 
obtained was dissolved in glacial acetic acid, filtered to remove inorganic salts, and 
relyophilized. The crude cyclic peptides were purified by preparative HPLC on the 
system described above, using a gradient of 0.1% aqueous TFA for 20 min, then 0-20% 
acetonitrile in 5 min, followed by 20-60% acetonitrile in 40 min, all at 5 ml/min. Again 
the peptides eluted near organic/0.1% aqueous TFA 1:1. The purity of the cyclic 
peptides was checked by analytical HPLC (Phenomenex Luna 5μ, 100 Å, 150x4.6 mm), 
using a Shimadzu SPD 10AVP with detection at 230 and 254 nm and by TLC in four 
solvent systems in silica gel with detection by UV light, iodine vapours, and ninhydrin. 
The analytical data of the compounds synthesized are given in the Supporting 
Information. 
Analgesic Peptides Synthesis: All products were synthesized in solution using the 
EDC/HOBt/DIPEA coupling method. The Nα terminal Boc-protected peptides were all 
deprotected by a mixture of TFA in DCM 1:1 at r.t. The intermediate TFA salts were 
used for subsequent reactions without further purification. Boc protected 
intermediate products were purified by silica gel column chromatography, or in case of 
scarcely soluble products, the purification was performed by trituration in EtOAc. The 
disulfide bond formation was achieved oxydizing the intermetiates by I2 in MeOH for 
3h at room temperature Final products were purified by RP-HPLC using a Waters 
XBridgeTM Prep BEH130 C18, 5.0 μm, 250 mm x 10 mm column at a flow rate of 1 
mL/min on a Waters Binary pump 1525, using as eluent a linear gradient of 
H2O/acetonitrile 0.1 % TFA starting from 5 % acetonitrile to 90 % acetonitrile in 45 min. 
The purity of the Nα-Boc-protected products was confirmed by NMR analysis on a 
Varian VXR 300 MHz instrument and mass spectrometry ESI-HRMS (Thermo Finnigan). 
The purity of all final TFA salts 2 was confirmed by NMR analysis, ESI-HRMS and by 
analytical RP-HPLC (C18-bonded 4.6 x 150 mm) at a flow rate of 1 mL/min using as 
eluent a gradient of H2O/acetonitrile 0.1% TFA ranging from 5% acetonitrile to 95 % 
acetonitrile in 50 min, and was found to be ≥ 95%. (Online Supporting Information 1.2, 
S2-5) 
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Synthesis of GRK2 inhibitor Peptides. The synthesis of GRK2 analogues was 
performed according to the solid phase approach using standard Fmoc methodology in 
a manual reaction vessel 176. Nα-Fmoc-protected amino acids, Rinkamide-resin, HOBt, 
HBTU, DIEA, Piperidine and Trifluoroacetic acid were purchased from Iris Biotech 
(Germany). Peptide synthesis solvents, reagents, as well as CH3CN for HPLC were 
reagent grade and were acquired from commercial sources and used without further 
purification unless otherwise noted. The first amino acid, NαFmoc-Xaa-OH (Xaa = Ile, 
Ser(tBu), Asp(tBu)), was linked on to the Rink resin (100–200 mesh, 1% DVB, 0.75 
mmol/g) previously deprotected by a 25% piperidine solution in DMF for 30 min. 
The following protected amino acids were then added stepwise: Nα-Fmoc-
His(N(im)trityl(Trt))-OH, N
α-Fmoc-DArg(Pbf)-OH (or Nα-Fmoc-DAla-OH) Nα-Fmoc-
Arg(Pbf)-OH, Nα-Fmoc-Leu-OH, Nα-Fmoc-Gly-OH. Each coupling reaction was 
accomplished using a 3-fold excess of amino acid with HBTU and HOBt in the presence 
of DIPEA (6 eq.). The Nα-Fmoc protecting groups was removed by treating the 
protected peptide resin with a 25% solution of piperidine in DMF (1x 5 min and 1x 25 
min). The peptide resin was washed three times with DMF, and the next coupling step 
was initiated in a stepwise manner. The peptide resin was washed with DCM (3×), DMF 
(3×), and DCM (3×), and the deprotection protocol was repeated after each coupling 
step. 
In addition, after each step of deprotection and after each coupling step, Kaiser test 
was performed to confirm the complete removal of the Fmoc protecting group, 
respectively, and to verify that complete coupling has occurred on all the free amines 
on the resin. 
The N-terminal Fmoc group was removed as described above, and the peptide was 
released from the resin with TFA/ iPr3SiH /H2O (90:5:5) for 3 h. The resin was removed 
by filtration, and the crude peptide was recovered by precipitation with cold 
anhydrous ethyl ether to give a white powder and then lyophilized. 
Synthesis of Head-to-tail cyclic peptides (4 and 5). The title peptides were 
synthesized using a 2-chlorotrityl chloride resin. The first Nα-Fmoc amino acid (0.6–1.2 
equiv relative to the resin for 2-chlorotrityl resin) and DIPEA (4 equiv relative to amino 
acid) were dissolved in dry dichloromethane (DCM) (approx. 10 mL per gram of resin) 
containing, if necessary, a small amount of dry DMF (enough to facilitate dissolution of 
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the acid). This was added to the resin and stirred for 30–120 min. After stirring, the 
resin was washed with 3×DCM/MeOH/DIPEA (17:2:1), 3 × DCM, 2 × DMF and 2 × DCM. 
Other Nα-Fmoc amino acids (4 equiv.) were sequentially coupled as previously 
described. The final cleavage with AcOH/MeOH/DCM (1:1:8) resulted in protected 
peptides. 
General procedure for cyclization: A solution of the linear protected peptide (0.03 
mmol) in DMF (6.5 mL) was added at room temperature to a reaction flask containing 
a solution of N-hydroxybenzotriazole (HOBt) (3 equiv, 12 mg, 0.09 mmol), HBTU (3 
equiv, 34 mg, 0.09 mmol) and DIPEA (5 equiv, 0.26 mL, 1.5 mmol) in DMF (1 mL). The 
mixture was stirred for 24 h at room temperature and monitored by TLC. The mixture 
was concentrated under reduced pressure, and the residue was dissolved in ethyl 
acetate (AcOEt). The organic phase was washed twice with 5% aqueous sodium 
bicarbonate (NaHCO3), dried over sodium sulfate (Na2SO4), and filtered. The solvent 
was removed by reduced pressure to give the final crude protected peptide. 
Synthesis of Lactam Analogues (6, 7, 8, and 9). The corresponding linear peptides 
were synthetized as described above and the amino acids Nα-Fmoc-Asp(Allyl)-OH and 
Nα-Fmoc-Lys(Alloc)-OH were used as lactam precursors.180 After linear assembly, the 
Nα-Alloc and the Allyl groups were removed according to the following procedure: 200 
mg of peptide resin was washed with dichloromethane (DCM) under Ar and a solution 
of PhSiH3 (24 equiv) in 2 mL of DCM was added. Subsequently a solution of Pd(PPh3)4 
(0.25 equiv) in 6 mL of DCM was added and the reaction was allowed to proceed under 
Ar for 30min. The peptide resin was washed with DCM (3x), DMF (3x) and DCM (4x), 
and the deprotection protocol was repeated (3x). The macrocyclic lactam ring 
formation was mediated by addition of HBTU (6 equiv), HOBt (6 equiv) and DIPEA (12 
equiv) for 2 h.180. The process was repeated if necessary (Kaiser test used to monitor 
completion). The N-terminal Fmoc group was removed and the peptide was released 
from the resin as described above. 
Side-chain deprotection. The protected cyclopeptide (0.02 mmol) was treated with 
10 mL of a solution of TFA/triisopropylsilane (TIS)/H2O 95:2.5:2.5 at room 
temperature. After 24 h, the reaction mixture was evaporated in vacuo, and the 
residue was washed with diethyl ether (Et2O) and concentrated in vacuo, yielding the 
side chain-deprotected cyclopeptide as a trifluoroacetate salt (quant.). 
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Synthesis of labeled peptides (Fl-3, Fl-7). Amino-terminal labeling of peptides with 
5(6)-carboxyfluorescein was performed. The corresponding peptides were synthetized 
as described above. Fmoc-deprotected, resin-bound peptides were reacted with 3 eq 
of 5(6)-carboxyfluorescein, N,N′-diisopropyl carbodiimide, and 1-hydroxybenzotriazol, 
each in DMF for 16 h in 10-ml syringes on a shaker at RT. Reactions were stopped by 
washing the resins three times each with DMF, methanol, dichloromethane, and 
diethyl ether. Completeness of amine acylation was confirmed using the Kaiser test. 
Purification and characterization. All crude peptides were purified by RP-HPLC on a 
semipreparative C18-bonded silica column (Phenomenex, Jupiter, 250×10mm) using a 
Shimadzu SPD 10A UV/VIS detector, with detection at 210 and 254 nm. The column 
was perfused at a flow rate of 3 ml/min with solvent A (10%, v/ v, water in 0.1% 
aqueous TFA), and a linear gradient from 10 to 90% of solvent B (80%, v/v, acetonitrile 
in 0.1% aqueous TFA) over 40 min was adopted for peptide elution. Analytical purity 
and retention time (tR, Table 2) of each peptide were determined using HPLC 
conditions in the above solvent system (solvents A and B) programmed at a flow rate 
of 1 mL/min using a linear gradient from 10 to 90% B over 25 min, fitted with C-18 
column Phenomenex, Juppiter C-18 column (250× 4,60 mm; 5µ). 
All analogues showed >97% purity when monitored at 215 nm. Homogeneous 
fractions, as established using analytical HPLC, were pooled and lyophilized. 
Peptides molecular weights were determined by ESI mass spectrometry. ESI-MS 
analysis in positive ion mode, were made using a Finnigan LCQ ion trap instrument, 
manufactured by Thermo Finnigan (San Jose, CA, USA), equipped with the Excalibur 
software for processing the data acquired. The sample was dissolved in a mixture of 
water and methanol (50/50) and injected directly into the electrospray source, using a 
syringe pump, which maintains constant flow at 5 µl/min. The temperature of the 
capillary was set at 220 °C. 
 
NMR METHODS AND STRUCTURAL CALCULATION 
Materials for NMR. 99.9% 2H2O were obtained from Aldrich (Milwaukee, USA), 
98% SDS-d25 and DPC-d38 were obtained from Cambridge Isotope Laboratories, Inc. 
(Andover, USA), [(2,2,3,3-tetradeuterio-3-(trimethylsilanyl)]propionic acid (TSP) from 
MSD Isotopes (Montreal, Canada). 
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NMR Spectroscopy. The samples for NMR spectroscopy were prepared by dissolving 
the appropriate amount of peptide in 0.45 ml of 1H2O (pH 5.5), 0.05 ml of 
2H2O to 
obtain a concentration 1-2 mM of peptide, and when occurring  200 mM of SDS-d25 and 
DPC-d38. NH exchange studies were performed dissolving peptides in 0.50 ml of 
2H2O 
and 200 mM of SDS-d25 or DPC-d38. NMR spectra were recorded on a Varian INOVA 700 
MHz spectrometer equipped with a z-gradient 5 mm triple-resonance probe head.. The 
spectra were calibrated relative to TSP (0.00 ppm) as internal standard. One-
dimensional (1D) NMR spectra were recorded in the Fourier mode with quadrature 
detection. The water signal was suppressed by The water signal was suppressed by 
gradient echo 188  2D DQF-COSY,32,33 TOCSY,34 and NOESYErrore. Il segnalibro non è definito.  
spectra were recorded in the phase-sensitive mode using the method from 
States.189Data block sizes were 2048 addresses in t2 and 512 equidistant t1 values. 
Before Fourier transformation, the time domain data matrices were multiplied by 
shifted sin2 functions in both dimensions. A mixing time of 70 ms was used for the 
TOCSY experiments. NOESY experiments were run with mixing times in the range of 
150-300 ms. The qualitative and quantitative analyses of DQF-COSY, TOCSY, and NOESY 
spectra, were obtained using the interactive program package XEASY.35 JHN-Hα coupling 
constants were obtained from 1D 1H NMR and 2D DQF-COSY spectra. All the spectra 
were recorded at a temperature of 25 °C, while for the temperature coefficients of the 
amide proton chemical shifts were calculated from 1D 1H NMR and 2D TOCSY 
experiments performed at different temperatures in the range 25°-40 °C by means of 
linear regression. 
 
Structural Determinations. The NOE-based distance restraints were obtained from 
NOESY spectra collected with a mixing time of 200 ms. The NOE cross peaks were 
integrated with the XEASY program and were converted into upper distance bounds 
using the CALIBA program incorporated into the program package DYANA.178 Cross 
peaks which were overlapped more than 50% were treated as weak restraints in the 
DYANA calculation. In a first step only NOE derived constraints (Supporting 
Information) were considered in the annealing procedures. For each examined 
peptide, an ensemble of 200 structures was generated with the simulated annealing of 
the program DYANA. An error-tolerant target function (tf-type=3) was used to account 
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for the peptide intrinsic flexibility. All the non standard amino acid (i.e. Pen, DPen, Tpi, 
DTpi, DTrp, Orn, (pCN)Phe and (3,4-Cl)Phe residues) were added to DYANA residue 
library using MOLMOL.190 From these structures we could univocally determine the 
hydrogen bond atom acceptors corresponding to the slowly exchanging NH’s 
previously determined for each peptide. In presence of H-bonds, in a second DYANA 
run these hydrogen bonds were explicitly added as upper and lower limit constraints 
together with the NOE derived upper limit constraints (Supporting Information). The 
second annealing procedure produced 200 conformations from which 50 structures 
were chosen, whose interprotonic distances best fitted NOE derived distances, and 
then refined through successive steps of restrained and unrestrained EM calculations 
using the Discover algorithm (Accelrys, San Diego, CA) and the consistent valence force 
field (CVFF).191 The final structures were analyzed using the InsightII program (Accelrys, 
San Diego, CA). Graphical representation were carried out with the InsightII program 
(Accelrys, San Diego, CA). RMS deviation analysis between energy minimized 
structures were carried out with the program MOLMOL.190 
 
DOCKING PROCEDURES. 
The new version of the docking program AutoDock4 (AD4)192, as implemented through 
the graphical user interface called AutoDockTools (ADT), was used to rigid docking of 
the Urantide NMR lowest energy structure and a theoretical structure of the h-UT 
receptor recently described.43  
Urantide and the receptor structure were converted to AD4 format files using ADT 
generating automatically all other atom values. The docking area was centered around 
the putative binding site. A set of grids of 60 Å × 60 Å × 60 Å with 0.375 Å spacing was 
calculated around the docking area for the ligand atom types using AutoGrid4. For 
each ligand, 100 separate docking calculations were performed. Each docking 
calculation consisted of 10 million energy evaluations using the Lamarckian genetic 
algorithm local search (GALS) method. The GALS method evaluates a population of 
possible docking solutions and propagates the most successful individuals from each 
generation into the subsequent generation of possible solutions. A low-frequency local 
search according to the method of Solis and Wets is applied to docking trials to ensure 
that the final solution represents a local minimum. All dockings described in this paper 
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were performed with a population size of 250, and 300 rounds of Solis and Wets local 
search were applied with a probability of 0.06. A mutation rate of 0.02 and a crossover 
rate of 0.8 were used to generate new docking trials for subsequent generations, and 
the best individual from each generation was propagated over the next generation. 
The docking results from each of the 100 calculations were clustered on the basis of 
root-mean square deviation (rmsd) (solutions differing by less than 2.0 Å) between the 
Cartesian coordinates of the atoms and were ranked on the basis of free energy of 
binding (ΔGAD4). Because AD4 does not perform any structural optimization and 
energy minimization of the complexes found, a molecular mechanics/energy 
minimization (MM/EM) approach was applied to refine the AD4 output. Refinement of 
the complexes were achieved by in vacuo energy minimization with the Discover 
algorithm (ɛ = 1) using the steepest descent and conjugate gradient methods until a 
rmsd of 0.05 kcal/mol per Å was reached. Calculations converged towards a single 
solution in which the lowest energy (ΔGAD4) binding conformation was also belonging 
to the most populated cluster (focc=85/100). This conformation was chosen as starting 
point for subsequent 1 ns MD simulations (time step = 1 fs, T = 300 K) using the 
Discover algorithm (Accelrys, San Diego, CA) and the consistent valence force field 
(CVFF)191. The backbone coordinates of the TM helices were fixed during the MD 
simulations because, without environmental constraints (i.e. lipid bilayer and water 
solution), they can move away from each other and can lose their helical structure. MD 
trajectory was analyzed by means of the Analysis module of InsightII package. Complex 
picture was rendered employing the UCSF Chimera software193.  Rescoring of the 
ligand/receptor models according to the AD4192  scoring function was attained using a 
script provided within the MGLTools software package (http://mgltools.scripps.edu/).  
 
h-UTR New Model and Docking.Three-dimensional structure predictions of h-UTR 
were generated by I-TASSER server for protein structure and function prediction, 
which is based on a threading alignment algorithm.63,64,65 Five models of h-UTR were 
obtained using I-TASSER servers. The best scored model (Model 1, see 1.1.4 Results 
section) was used for docking studies. 
The initial poses for the h-UTR–URP complex are generated by docking the lowest 
energy conformers of URP obtained by NMR to the h-UTR model using the program 
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HADDOCK 2.0.72,73 For comparative purpose, also the best scored NMR structure of 
hU-II.28 was docked to the same h-UTR model. Only the distance between Nɛ of Lys8 
and carboxyl oxygens of Asp130 on TM3 was used as a restraint (2.7±1 Å) in the 
docking studies since the last residue is generally regarded as the ligand recognition 
site.64 
Considering the receptor, only the side chains of residues engaged in orthosteric 
ligand/GPCR binding in the complexes used as templates by I-Tasser (PDB ID’s: 4n6h, 
4dkl, 4buo; see Results section) were considered flexible in the docking procedure 
(active residue: W116, L126, F127, D130, F131, M134, V184, M188, H208, L212, F274, 
W275, W277, Q278, Y305). Instead, all peptide’s atoms were held frozen (passive 
residue).  
Refinement of each pose was achieved by in vacuo energy minimization with the 
Discover algorithm using the steepest descent and conjugate gradient methods until a 
RMSD of 0.05 kcal/mol per Å was reached. The backbone atoms of the TM and IL 
domains of the h-UTR were held in their position; the ligand and EL’s were free to 
relax. Molecular graphics images of the complexes were produced using the UCSF 
Chimera package. 193 
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BIOLOGICAL ASSAYS  
1.1-Peptides UTII analogues 
Organ Bath Experiments. The experimental procedures employed in this study were 
approved by Institutional Animal Care and Use Committee and carried out in 
accordance with the legislation of Italian authorities (D.L. 116 27/01/1992), which 
complies with European Community guidelines (CEE Directive 86/609) for the care and 
use of experimental animals. 
Male albino rats (Wistar strain, 275–350 g; Harlan Laboratories, UD, Italy) were 
euthanized by cervical dislocation, under ether anesthesia. The thoracic aorta was 
cleared of surrounding tissue and excised from the aortic arch to the diaphragm. From 
each vessel, a helically cut strip was prepared, and then it was cut into two parallel 
strips. The endothelium was removed by gently rubbing the vessel intimal surface with 
a cotton-tip applicator; the effectiveness of this maneuver was assessed by the loss of 
relaxation response to acetylcholine (1 µM) in noradrenaline (1 µM) precontracted 
preparations. All preparations were placed in 5 ml organ baths filled with normal Krebs 
solution of the following composition (mmol/l): NaCl 119; NaHCO3 25; KH2PO4 1.2; 
MgSO4 1.5; CaCl2 2.5; KCl 4.7 and glucose 11, warmed at 37 °C and oxygenated with 
95% O2, 5% CO2. The tissues were connected to isotonic force transducers (Ugo Basile, 
VA, Italy) under a constant load of 5 mN and motor activity was digitally recorded by 
an Octal Bridge Amplifier connected to PowerLab/8sp hardware system and analyzed 
using the Chart 4.2 software (ADInstruments Ltd, Oxford, UK). After 60 min 
equilibration, tissue responsiveness was assessed by the addition of 1 µM 
noradrenaline followed by a further equilibration of 60 min. 
To assess the agonist activity cumulative concentration-response curves to hU-II and to 
the agonist peptide under examination were constructed in paired aortic strips and 
responses obtained were normalized towards the control hU-II maximal contractile 
effect (Emax). 
To assess the antagonist activity concentration–response curves to hU-II were 
constructed cumulatively in paired aortic strips. One strip was pretreated with vehicle 
(DMSO; 1-3 µl/ml) and used as a control, while the other strip was pretreated with the 
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antagonist peptide under examination and, after a 30-min incubation period, hU-II was 
administered cumulatively to both preparations. 
In each preparation only one cumulative concentration-response curve to hU-II was 
carried out and only one concentration of antagonist was tested. Concentration-
response curves were analyzed by sigmoidal nonlinear regression fit using the 
GraphPad Prism 4.0 program (San Diego, CA, U.S.A.) to determine the molar 
concentration of the agonist producing the 50% (EC50) of its maximal effect. Agonist 
activity of all compounds was expressed as pEC50 (−log EC50). The antagonist potency 
was expressed in terms of pKB estimated as the mean of the individual values obtained 
with the Gaddum equation: pKB=log(CR-1)-log[B] were CR is the concentration-ratio 
calculated from equieffective concentrations of agonist (EC50) obtained in the presence 
and in the absence of antagonist and B is the used antagonist concentration.194,195,196 
Competitive antagonism was checked by the Schild regression analysis by plotting the 
estimates of log(CR-1) against log[B] to determine the slopes of linear regression: a 
plot with linear regression line and slope not significantly different from unity was 
considered as proof of competitive antagonism.194,195,196 
Results were compared for significant differences using two-tail Student’s t-test for 
paired data or one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc 
test. A p value <0.05 was considered statistically significant. 
Binding experiments. All experiments were performed on membranes obtained from 
stable CHO-K1 cells expressing the recombinant human UT receptor (ES-440-M, lots 
564-915-A and 613-577-A, Perkin Elmer, Boston, MA, USA). Assay conditions were: 
TRIS-buffer (20mM, pH 7.4 at 37° C) added with MgCl2 (5mM) and 0.5% BSA. Final 
assay volume was 0.1 ml, containing 1 or 20 µg membrane proteins depending on the 
lot of provided membranes. The radioligand used for competition experiments was 
[125I]Urotensin II (specific activity 2200 Ci/mmol; NEX379, Perkin Elmer) in the range 
0.07–1.4 nM (as recommended by the lot of provided membranes). Non-specific 
binding was determined in the presence of 1 µM of unlabelled hU-II, and ranged 
between 10–20% of total binding. Competing ligands were tested in a wide range of 
concentrations (1 pM – 10 µM). The incubation period (120 min at 37° C) was 
terminated by rapid filtration through UniFilter-96 plates (Packard Instrument 
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Company), pre-soaked for at least 2 h in BSA 0.5%, and using a MicroMate 96 Cell 
Harvester (Packard Instrument Company). The filters were then washed 4 times with 
0.2 ml aliquots of Tris-HCl buffer (20mM, pH 7.4, 4°C). Filters were dried and soaked in 
Microscint 40 (50 µl in each well, Packard Instrument Company), and bound 
radioactivity was counted by a TopCount Microplate Scintillation Counter (Packard 
Instrument Company). Determinations were performed in duplicate. All binding data 
were fitted by using GraphPad Prism 4.0 in order to determine the equilibrium 
dissociation constant (Kd) from homologous competition experiments, the ligand 
concentration inhibiting the radioligand binding of the 50% (IC50) from heterologous 
competition experiments. Ki values were calculated from IC50 using the Cheng-Prusoff 
equation (Ki = IC50/(1 + [radioligand]/Kd) according to the concentration and Kd of the 
radioligand.194,195,196 In each experimental section one homologous competition curve 
to urotensin-II was run and the calculated Kd and the used radioligand concentration 
were used for the determination of ligand Ki values. The determine Kd value was 2.23 
nM (1.09 – 3.38 nM, 95% c.l., n = 5, each experiment performed in duplicate). 
Intracellular Calcium Assay: The intracellular calcium assay was performed by 
DiscoveRx (Fremont, CA, USA) using a HitHunter Calcium No Wash Plus Assay Kit from 
DiscoveRx Inc. (Fremont, CA) and  UT-CHO–K1 cells transfected with the cDNA 
encoding UT-II human receptor.  
Twenty four hours prior to assay cells were seeded at 10000 cells per well of a 384-well 
plate (Greiner, black optical poly-D-lysine coated) in 20 µl cell plating reagent 2 
(DiscoveRx) and incubated overnight at 37°C. Cells were loaded with Calcium No 
WashPLUS kit (DiscoveRx) for 45 minutes at 37°C + 15 minutes at room temperature in 
the presence of probenecid (5 mM).197Compound addition and calcium mobilization 
were monitored on a FLIPRTETRA (Molecular Devices, Sunnyvale, CA). 
Serum peptides stability: Peptide stabilities were assayed in diluted serum as 
previously described.198,199 25% fetal calf serum was centrifuged at 13,000 rpm for 10 
min to remove lipids and the supernatant was collected and incubated at 37 °C for at 
least 15 min. The assay was initiated upon the addition of peptides to the serum for a 
final peptide concentration of 80 µM. 80 µL aliquots of the incubations were taken for 
the following time points: 0, 4, 16, 20, 24, 36 h. The aliquots were mixed with 40 µL of 
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15% trichloroacetic acid (TCA) and incubated at 2 °C for at least 15 min to precipitate 
serum proteins. The supernatant was collected for each sample after centrifugation at 
13,000 rpm for 10 min. These assays were performed in triplicate. Reverse phase high 
performance liquid chromatography (RP-HPLC) was carried out on an Agilent 
Technologies 1200 series HPLC equipped with UV detector using a C18 column from 
ThermoFisher (Milan, Italy). Gradient elution was performed at 25°C (monitoring at 
210 nm) in a gradient starting with buffer A (0.1 % TFA in water) and applying buffer B 
(0.1 % TFA in acetonitrile) from 5 to 70 % in 15 min (Online Supporting 
Information1.1.3, Figure S1). 
1.2 Analgesic Peptides 
Chemicals Tris-HCl, EGTA, NaCl, MgCl2·6 H2O, GDP, the GTP analogue GTPγS, and the κ 
opioid receptor specific agonist U69593 were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The radiolabelled GTP analogue, [35S]GTPγS (specific activity: >1000 
Ci/mmol) was purchased from the Isotope Institute Ltd. (Budapest, Hungary). The μ 
opioid receptor specific enkephalin analogue Tyr-D-Ala- Gly-(NMe)Phe-Gly-ol (DAMGO) 
was obtained from Bachem Holding AG (Bubendorf, Switzerland). The modified δ 
opioid receptor specific deltorphin II derivative, Ile5,6deltorphin II was synthesized and 
tritiated ([3H]Ile5,6deltorphin II; specific activity: 28 Ci/mmol) in the Isotope Laboratory 
of BRC (Szeged, Hungary) together with the tritiated DAMGO ([3H]DAMGO; specific 
activity: 41 Ci/mmol. Tritiated [3H]U69593, specific activity: 43,7 Ci/mmol) was 
purchased from PerkinElmer (Waltham, USA). The opioid antagonist naloxone was 
kindly provided by the company Endo Laboratories DuPont de Nemours (Wilmington, 
DE, USA). All applied receptor ligands were stored in 1 mM stock solution at -20 °C. 
 
Animals. Male Wistar rats (250–300g body weight) were housed in the local animal 
house of the Biological Research Center (BRC, Szeged, Hungary) in groups of 4 or 8 
animals and were maintained on a 12:12 hour of light/dark cycle. The animals were 
handled in accordance with the European Communities Council Directives 
(86/609/ECC) and the Hungarian Act for the Protection of Animals in Research 
(XXVIII.tv. 32.§). 
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Rat brain membrane preparations. Rats were decapitated and the brain was quickly 
removed, and homogenized on ice in 50 mM Tris-HCl buffer (pH 7.4) with a Teflon-
glass homogenizer. The homogenate was centrifuged at 40,000 x g for 20 min at 4 °C 
and the pellet was re-suspended in fresh buffer and incubated for 30 min at 37 °C. This 
centrifugation step was repeated, and the final pellet was resuspended in 50 mM Tris-
HCl buffer (pH 7.4) containing 0.32 M sucrose and stored at -80 °C until use.  
 
Cell culture and cell membrane preparations. Chinese hamster ovary cells (CHO) 
overexpressing the appropriate opioid receptors, such as mouse δ and human κ and μ 
opioid receptors were provided by Dr. Zvi Vogel (Rehovot, Israel). The cells were grown 
in Dulbecco’s modified Eagle’s medium and in α-minimum essential medium, 
respectively. Both media were supplemented with 10% fetal calf serum, 2 mM 
glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 25 mg/ml fungizone and 0.5 
mg/ml geneticin. Cells were kept in culture at 37 °C in a humidified atmosphere 
consisting of 5% CO2 and 95% air. Membranes were prepared from subconfluent 
cultures. Cells were rinsed three times with 10 ml PBS and removed with 50 mM Tris–
HCl pH 7.4, 1 mM EGTA, 1 mM EDTA and 0.1 mM PMSF buffer and homogenized for 15 
s with a polytron homogenize in an ice-bath. Homogenates were centrifuged two times 
at 18,000 g for 20 min. The final pellet was resuspended in the above buffer and stored 
in aliquots at -80 °C until use. 
 
Competition binding experiments. Aliquots of frozen rat brain membranes were first 
centrifuged (40000 × g, 20 min, 4 °C) to remove sucrose and the pellets were 
suspended in 50 mM Tris-HCl buffer (pH 7.4). Membranes were incubated with gentle 
shaking with the appropriate incubation conditions depending on the opioid 
radioligand ([3H]DAMGO: 35 °C for 60 min; [3H]Ile5,6deltorphin II: 35 °C for 35 min; 
[3H]U69593 at 30 °C for 60 min) in a final volume of 1 ml. The incubation mixture also 
contained 10-10 – 10-5 M concentration interval of unlabeled compound 9 and 10 
together with DAMGO or Ile5,6deltorphin II or U69593 for control  together with ~ 1 nM 
of the appropriate tritiated opioid receptor specific ligand. Total binding was measured 
in the presence of radioligand, in the absence of the competitor ligands. The non-
specific binding was determined in the presence of 10 μM unlabeled naloxone. The 
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reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell 
Harvester), and washed three times with 5 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer 
through Whatman GF/C ([3H]DAMGO and [3H]Ile5,6deltorphin II) or GF/B glass fiber 
filters ([3H]U69593 the filter was also pretreated in 3% polyethyleneimine for 60 min to 
reduce non-specific binding) (Online Supporting Information1.2, Figure S1). The 
radioactivity of the filters was detected in UltimaGoldTM MV aqueous scintillation 
cocktail with Packard Tricarb 2300TR liquid scintillation counter. The competition 
binding assays were performed in duplicate and repeated at least three times. 
 
Functional [35S]GTPγS binding assays. The G-protein activation of the opioid 
receptors were measured in functional [35S]GTPγS binding experiments, which 
monitors the nucleotide exchange process of the Gα-protein using a non-hydrolysable 
radiolabeled GTP analog, 35[S]GTPγS in the presence of increasing concentrations of 
the observed ligand (Online Supporting Information1.2, Figure S2). The assays were 
performed as previously described,8 with slight modifications. Membrane fractions of 
CHO cell lines overexpressed with the corresponding opioid receptors were incubated 
in a final volume of 1 ml at 30˚C for 60 min in Tris-EGTA buffer (pH 7.4; 50 mM Tris-HCl, 
1 mM EGTA, 3 mM MgCl2, 100 mM NaCl). [35S]GTPγS (20 MBq/0.05 cm3 ) was added 
in 0.05 nM concentrations together with compounds 9 and 10 and DAMGO, 
Ile5,6deltorphin II, U69593 biphalin for control in increasing concentrations (10-10 – 10-
5 M). Total binding (T) was measured in the absence of the ligands, non-specific binding 
(NS) was determined in the presence of 10 µM unlabeled GTPγS and subtracted from 
total binding. The difference (T−NS) represents basal activity. Bound and free 
[35S]GTPγS were separated by vacuum filtration through Whatman GF/B filters with 
Brandel M24R Cell harvester. Filters were washed three times with 5 ml ice-cold buffer 
(pH 7.4), and the radioactivity of the dried filters was detected in UltimaGoldTM MV 
scintillation cocktail with Packard Tricarb 2300TR liquid scintillation counter. The 
[35S]GTPγS binding experiments were performed in triplicates and repeated at least 
three times. 
 
Data analysis. Experimental data were presented as means ± S.E.M. and were fitted 
using nonlinear regression with the curve fitting program, GraphPad Prism 5.0 
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(GraphPad Prism Software Inc., San Diego, CA),. During the competition binding assays 
the ‘One-site competition’ fitting equation was applied to determine the inhibition 
constant (Ki). The inhibition of the specifically bound tritiated opioid receptor specific 
ligand was given in percentage, the total specific binding and the non-specific binding 
was defined as 100% and 0% respectively. In the [35S]GTPγS binding assays the 
‘Sigmoid dose-response’ fitting was used to establish the maximal stimulation or 
efficacy (Emax) of the receptor, and the potency (EC50) of the stimulator ligand. The 
receptor stimulation was given as percent of the specific [35S]GTPγS binding observed 
over the basal activity, which was S9 settled as 100%. In case of three or more data 
sets One-way ANOVA with Bonferroni’s Multiple Comparison post hoc test was 
performed to determine the significance level, using GraphPad Prism 5.0. Significance 
was accepted at the P < 0.05 level. 
 
GPI and MVD in vitro bioassays Electrically induced smooth muscle contractions of 
mouse vas deferens and strips of guinea pig ileum longitudinal muscle myenteric 
plexus were used. Tissues came from male ICR mice weighing 25-30 g and from male 
Hartley guinea pigs weighing 150-400 g. The tissues were first tied to gold chains with 
suture silk, suspended in 20 mL baths containing 37 °C oxygenated (95% O2, 5% CO2), 
Krebs bicarbonate solution (magnesium-free for the MVD), and allowed to equilibrate 
for 15 min. Tissues were then stretched to optimal length previously determined to be 
1 g tension, allowed to equilibrate for 15 min. The tissues were stimulated 
transmurally between platinum plate electrodes at 0.1 Hz, 0.4 ms pulses (2.0 ms pulses 
for MVD) at supramaximal voltage. Endomorphin-2 and analogues 9 e 10 at five to 
seven different concentrations were added to the baths in 20-60 mL volumes to 
produce cumulative doseeresponse curves. Percent inhibition was calculated by using 
an average contraction height for 1 min preceding the addition of the peptide divided 
by contraction height 3 min after the exposure to the peptide. IC50 values are the mean 
of not less than four separate assays. IC50 estimates and their associated standard 
errors were determined by fitting the mean data to the Hill equation using a 
computerized least-squares method. 
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In vivo Nociception Test. 
Animals. Male CD-1 mice (Harlan, Italy) weighing 25-30 g were used for all 
experiments. Mice were housed for at least 1 week before experimental sessions in 
colony cages (7 mice in each cage) under standard light (light on from 7.00 a.m. to 7.00 
p.m.), temperature (21 ± 1 °C), relative humidity (60 ± 10%) with food and water 
available ad libitum. The experiments conformed to the guidelines for pain research 
with laboratory animals. The research protocol was approved by the Service for 
Biotechnology and Animal Welfare of the Istituto Superiore di Sanità and authorized by 
the Italian Ministry of Health, according to Legislative Decree 116/92, which 
implemented the European Directive 86/609/EEC on laboratory animal protection in 
Italy. Animal welfare was routinely checked by veterinarians from the Service for 
Biotechnology and Animal Welfare.  
Drugs and treatment procedure. DMSO was purchased from Merck (Italy). Morphine 
Sulphate was purchased from SALARS (Italy). On each test day, morphine or peptide 
solutions were freshly prepared using DMSO: 0.9 % saline 1:5 v/v. These solutions 
were injected at a volume of 5 μL/mouse for intracerebroventricular (i.c.v.) and 5 
mL/Kg for intravenous (i.v.) administrations. 
 
Surgery for i.c.v. injections. For i.c.v. injections, mice were lightly anesthetized with 
isoflurane, and an incision was made in the scalp. Injections were performed using a 10 
μl Hamilton microsyringe at a point 2-mm caudal and 2-mm lateral from the bregma at 
a depth of 3 mm in a volume of 5 μL.  
 
Surgery for i.v. injections. For i.v. injections, mice were lightly anesthetized with 
isoflurane, gentle constrained by using a glove and intravenous injection performed 
directly into the tail vein using a 500 μl Hamilton syringe equipped with a 30 gauge 
needle in a volume of 5 ml/kg. 
 
Hot plate and tail flick tests. Thermal nociception (hot plate test) was assessed with a 
commercially available apparatus consisting of a metal plate 25x25 cm (Ugo Basile, 
Italy) heated to a constant temperature of 55.0 ± 0.1° C, on which a plastic cylinder (20 
cm diameter, 18 cm high) was placed. The time of latency (s) was recorded from the 
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moment the animal was placed in the cylinder on the hot plate until it licked its paws 
or jumped; the cut-off time was 60 s. The baseline was calculated as mean of three 
readings recorded before testing at intervals of 15 min. The time course of latency was 
then determined at 15, 30, 45, 60, 90 and 120 min after compound treatment (for i.v. 
administration until to 180 min). The tail-flick latency was obtained using a commercial 
unit (Ugo Basile, Italy), consisting of an infrared radiant light source (100 W, 15 V bulb) 
focused onto a photocell utilizing an aluminium parabolic mirror. During the trials the 
mice were gently hand-restrained with a glove. Radiant heat was focused 3-4 cm from 
the tip of the tail, and the latency (s) of the tail withdrawal recorded. The 
measurement was interrupted if the latency exceeded the cut off time (15 s at 15 V). 
Also in this case, the baseline was calculated as mean of three readings recorded 
before testing at intervals of 15 min and the time course of latency determined at 15, 
30, 45, 60, 90 and 120 min after treatment (for i.v. administration until to 180 min). In 
both the hot plate and tail flick tests, data were expressed as time course of the 
percentage of maximum effect (%MPE) = (post drug latency – baseline latency) / (cut-
off time – baseline latency) x 100. 
Data analysis and statistics. Experimental data were expressed as mean ± S.E.M. The 
significance among groups was evaluated with the analysis of variance (two-way 
ANOVA test) followed by Bonferroni’s post-hoc comparisons using the statistical 
software SPSS. Statistical significance was assumed at P<0.05 (*P<0.05; ***P<0.005) 
  
Chapter 1 
 
 86  
 
1.3-Peptides GRK2 Inhibitors 
GRK Activity in Rhodopsin Phosphorylation Assays. To evaluate the effect of all 
synthesized peptides on GRK2 activity we assessed GRK2 or GRK5 purified proteins by 
light-dependent phosphorylation of rhodopsin-enriched rod outer segment 
membranes (ROS) using [γ-32P]-ATP as previously described.200 Briefly, 50 ng of active 
GRK2 or GRK5 were incubated with ROS membranes in presence or absence of 
inhibitor peptides in reaction buffer (25 µl) containing 10 mM MgCl2, 20 mM Tris-Cl, 2 
mM EDTA, 5 mM EGTA, and 0.1 mM ATP and 10 μCi of [32P]γ‐ATP. After incubation 
with white light for 15 minutes at room temperature, the reaction was quenched with 
ice-cold lysis buffer and centrifuged for 15 minutes at 13000g. The pelleted material 
was resuspended in 35 μL protein gel loading dye, electrophorosed and resolved on 
SDSPAGE 4‐12% gradient (Invitrogen), stained with Coomassie blue, destained, vacuum 
dried, and exposed for autoradiography. Phosphorylated rhodopsin was visualized by 
autoradiography of dried gels and quantified using a PhosphorImager (Molecular 
Dynamics). Alternatively, the ROS pellet was washed twice in ice-cold lysis buffer to 
remove the unbound [γ32P]-ATP and then  resuspended in 100 μL of buffer and the 
level of [γ32P]-ATP incorporation into ROS was determined by liquid scintillation 
counter.  
 
β-Adrenoreceptor Radioligand Binding. Cultured Hembriogenic Kidney cells 
overexpressing β2adrenergic receptor (β2HEK-293) were treated with peptides 3 and 7 
1 μM for one hour.  Membrane fraction were prepared by homogenization of whole 
cell in ice-cold buffer (25 mM Tris-HCl (pH 7.5), 5 mM EDTA, 5 mM EGTA, 1 mM 
phenylmethylsulfonyl fluoride, 2 μg/ml each leupeptin and aprotinin) as previously 
described [34]. Total βAR density was determined by incubating 60 μg of sarcolemmal 
membranes with a saturating concentration of [125I]cyanopindolol and 20 µmol/L 
alprenolol to define nonspecific binding. Assays were conducted at 37 °C for 60 
minutes and then filtered over GF/C glass fiber filters (Whatman) that were washed 
and counted in a gamma counter.183 All values are presented as mean ± SEM of three 
independent experiments. One-way ANOVA was performed to compare the different 
groups. A significance level of P<0.05 was assumed for all statistical evaluations. 
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Statistics were computed with GraphPad Prism Software (GraphPad Software Inc., 
version 4, San Diego, CA, USA). 
 
cAMP synthesis. β2HEK-293 were plated in 96-well plates (10,000 cells/well) and 
serum starved overnight. Cells were incubated in a fresh medium in the presence 3 
and 7 peptides 1 μM for one hour and then stimulated with β adrenergic receptor 
agonist Isoproterenol 0.1 μM for 15 min. The cAMP quantification was evaluated by 
enzyme immunoassay, using an EIA commercial kit (RPN 2255 GE Healthcare Bio-
Sciences AB, Uppsala, Sweden). The cAMP content present in HEK- 293 cell was 
expressed in fmoles per well. All values are presented as mean ± SEM of three 
independent experiments. One-way ANOVA was performed to compare the different 
groups. A significance level of P<0.05 was assumed for all statistical evaluations. 
Statistics were computed with GraphPad Prism Software (GraphPad Software Inc., 
version 4, San Diego, CA, USA). 
Internalization studies. β2HEK-293 overexpressing human β2AR cells were plated in 4-
well ibidi plate (10,000 cells/well) and serum starved overnight. The cells were then 
incubated with fluorescently labelled peptides (Fl-3 and Fl-7) 1 M for 60 min at 37 °C. 
After washing twice with PBS cell images were taken by using an Eclipse E1000 
Fluorescence Microscope (Nikon) and acquired by using Sigma Scan Pro software 
(Jandel). Images were optimized for contrast in Adobe PhotoShop, but no further 
manipulations were made. 
Alternatively HEK-293 cells were plated in 24-well plates (20,000 cells/well) and serum 
starved overnight The cells were then incubated with fluorescently labelled peptides 
(Fl-3 and Fl-7) at the concentration of 10 and 1 μM for 60 min at 37 °C. The 
fluorescence incorporation was quantified on a Tecan Genios plate reader with a 485 
nm excitation filter and a 510 nm emission filter using a gain setting of 1.0. The 
background signal from cells untracted  was subtracted. All values are presented as 
mean ± SEM of three independent experiments. One-way ANOVA was performed to 
compare the different groups. A significance level of P<0.05 was assumed for all 
statistical evaluations. Statistics were computed with GraphPad Prism Software 
(GraphPad Software Inc., version 4, San Diego, CA, USA)  
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SUPPORTING INFORMATION 
1.1.1 “New Insight into the Binding Mode of Peptides at Urotensin-II Receptor by Trp-
Constrained Analogues of P5U and Urantide” Supplementary data can be found at 
http://onlinelibrary.wiley.com/doi/10.1002/psc.2498/suppinfo  
1.1.2 “Urantide Conformation and Interaction with Urotensin-II" Receptor” 
Supplementary data can be found at: 
http://onlinelibrary.wiley.com/doi/10.1002/ardp.201300269/suppinfo  
1.1.3 “Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at 
the Urotensin-II Receptor” Supplementary data can be found at: 
http://pubs.acs.org/doi/suppl/10.1021/jm500218x  
1.1.4 “An Investigation into the Origin of the Biased Agonism Associated with the 
Urotensin-II Receptor Activation” Supplementary data can be found at: 
http://onlinelibrary.wiley.com/doi/10.1002/psc.2740/suppinfo  
1.2 “Novel Analgesic Peptides With Improved Antinociceptive Properties” 
Supplementary data can be found at : 
http://pubs.acs.org/doi/suppl/10.1021/ml500241n  
1.3.1 “SAR study and conformational analysis of novel peptides GRK2 inhibitors” 
Supplementary data can be found at: 
http://onlinelibrary.wiley.com/doi/10.1002/bip.22295/suppinfo  
1.3.2 “Design, synthesis and efficacy of novel cyclic peptides GRK2 inhibitors” 
Supplementary data can be found at: http://dx.doi.org/10.1016/j.ejmech.2013.08.039 
 
Furthermore, all the supporting information are available on email request at 
antonio.limatola@unina.it 
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CHAPTER 2 – MONITORING ALPHA‑SYNUCLEIN SITE-
SELECTIVE OXIDATION DAMAGE REPAIR IN 
MAMMALIAN CELLS BY HIGH RESOLUTION NMR 
SPECTROSCOPY 
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INTRODUCTION 
Lewy body diseases (LBDs) are a heterogeneous group of disorders that include 
Parkinson’s disease (PD), PD with dementia (PDD) and dementia with Lewy bodies 
(DLB).201 Together, these diseases affect over 5 million people worldwide. LBDs are 
often referred to as synucleinopathies because α-Syn has been identiﬁed as the major 
component of Lewy bodies and Lewy neurites, the characteristic proteinaceous 
deposits that are the hallmarks of PD.  
An increasing body of evidence from animal models as well as data from genetic, 
biochemical and biophysical studies support the hypothesis that the processes of α‑
Syn oligomerization 202 203  and fibril formation 204 205 have central roles in the 
pathogenesis of PD and other synucleinopathies.206 
Nevertheless, the molecular mechanisms by which α‑Syn aggregation contributes to 
neurodegeneration, the nature of the toxic forms of α‑Syn and the cellular pathways 
that are affected by α‑Syn remain largely unknown.  
Structure of α‑synuclein 
α-Syn is an intrinsically disordered protein, but can adopt a number of different 
conformational states depending on conditions and cofactors. α‑Syn is a 14 kDa 
protein (140 amino acids; pI ~ 4.7) characterized by an amphipathic lysine‑rich amino 
terminus, which has a crucial role in modulating its interactions with membranes207,208 
and a disordered, acidic carboxy‑terminal tail, which has been implicated in regulating 
its nuclear localization and interactions with metals, small molecules and proteins. 
209,210 The central region of α‑Syn was first purified from amyloid plaques in patients 
with Alzheimer’s disease (AD) 211 ; 212 It contains a highly hydrophobic motif that 
comprises 35 amino acid residues (Figure 1A) and is known as the non‑amyloid‑β 
component of AD amyloid plaques (NAC).212,212213,214 The NAC region is indispensable 
for α‑Syn aggregation; the deletion of large segments within this motif greatly 
diminished α‑Syn oligomerization and fibrillogenesis in vitro 214 215and in cell‑based 
assays.216 Studies by several groups using different biophysical methods (i.e., NMR, 
light scattering and circular dichroism) consistently showed that α‑Syn purified from 
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Escherichia coli under native or denaturing conditions exists predominantly as stable 
unfolded monomers.212,217,218 It is well established that α‑Syn adopts an α‑helical 
conformation upon binding to synthetic or biological membranes in vitro (Figure 1B). 
However, very little is known about the conformational state (or states) of α‑Syn in 
the different compartments of living cells. Several factors, including oxidative stress, 
post ‑ translational modifications205, proteolysi 219  and binding to fatty acids, 
phospholipids220 or metal ion, were shown to induce and/or modulate α‑Syn structure 
and oligomerization. 
 
Figure 1. α‑Syn sequence characterized by an amphipathic lysine‑rich amino terminus (1-60), NAC 
region(61-95 ) and acidic carboxy‑terminal tail (96-140 (A). Conformational states of α‑Syn (B). 
 
Oxidized α‑synuclein in Parkinson´s disease. 
The relationship between oxidative stress and brain damage induced by Syn 
aggregation has been firmly established by several lines of work. In fact, supporting 
this hypotheses, α ‑ Syn deposited in LBs from PD patients contain oxidative 
modifications, such as nitrated tyrosines and oxidized methionines. In particular 
methionine sidechains are susceptible to oxidation to sulfoxide and ultimately sulfone 
All four methionines in α‑Syn (Met-1, Met-5, Met-116, and Met-127) are highly 
susceptible to oxidation by intracellularreactive oxygen species (ROS) such as H2O2, O2
-, 
OH
.
, chloramines or peroxinitrite.221,222 It has been shown that Met oxidation promotes 
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the formation of intermediate oligomeric species of α‑Syn in vitro and these species 
presented different degrees of toxicity when added to cultured models 
cells.223,224,225,226 Furthermore, PC12 cells overexpressing α‑Syn and treated with 
rotenone (an inhibitor of mitochondrial complex I able to induce an oxidative stress by 
ROS production) accumulate methionine oxidized α‑Syn molecules 227 and primary 
dopaminergic cells treated with the same compound, show increased formation of α‑
Syn intracellular inclusion.228,229 Additionally, a wide variety of physiologically relevant 
interactions between α‑ Syn and copper ions or lipidic membranes results in 
sulfoxidation of Met1 and Met5 residues,220 while dopamine promotes sulfoxide 
formation at Met 127.225 
Reportedly, methionine-oxidized α ‑ Syn  has decreased affinity for biological 
membranes, and is poorly degraded by 20S proteasome in vitro and in live cells.230 
Furthermore, recent in vitro and in vivo studies established a link between oxidative 
stress, methionine oxidation and increased levels of Ser 129 phosphorylation (a 
pathological hallmark of in vivo α‑Syn deposits in PD patients).231. Altogether, these 
evidences suggested that oxidation of Met residues in α‑Syn is involved in intracellular 
α‑Syn aggregation and neurnal cell death. 
 
RESULTS 
Methionine oxidation influence α-Syn alpha-helical propensity and membrane 
binding 
First, we analyzed the structural consequences of Met oxidation in α‑Syn. To get the 
Met oxidized α‑Syn molecules, we pre-incubated 15N-isotopically enriched protein 
with 4% H2O2 for 1 hour at room temperature as previously reported.
232  This 
treatment result in the oxidation of all Met residues to corresponding sulfoxide 
species, without induction of any other modification on the protein(Figure S1-A, 
Supplementary data). In all of our experiments we used the N-terminally acetylated 
protein form that corresponds to the native state of α‑Syn.233 After removal of excess 
H2O2 by size exclusion chromatography (SEC), we confirmed full oxidation of Met 
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residues by 1H-15N HMQC experiments234 and we compared the biophysical properties 
of oxidized and reduced α‑Syn. Circular dichroism (CD), dynamic light scattering (DLS) 
and SEC experiments showed no major structural rearrangements of α‑Syn overall 
conformation (Figure S1-B, Supplementary data). Next we performed an NMR analysis 
of both α‑Syn species. A comparison of reduced and oxidized α‑Syn spectra revealed 
large chemical shifts perturbations for all the four methionine residues (Figure2-A). In 
particular, for Met116 and Met127 we detected two well-resolved cross-peaks for 
these groups reflecting the formation of a racemic mixture of the R and S methionine 
sulfoxide diasteroisomers. Although we could not assign each resonance to a particular 
absolute configuration of the sulphur atom, it was interesting to note that this feature 
was much less prominent for Met1 and Met5, indicating that different local 
conformational properties or neighboring amino acids induce different changes in 
chemical environment for R and S methionine sulfoxide at the N- and C- terminal 
regions. The 1H-15N MWCS analysis of oxidized and reduced α‑Syn revealed that 
chemical shifts changes at the N-terminus are more widespread than those at the C-
terminus where only the vicinity of the oxidized residues experience significant 
chemical shifts changes (Figure2-B,C). This observation suggests that local 
conformational rearrangements occur upon Met oxidation around position 1 and 5. To 
study these features in more detail we analyzed C-alfa secondary chemical shifts for 
reduced and oxidized α‑Syn , respectively. Secondary chemical shifts are widely used 
to determine secondary structure content in proteins and peptides as deviations of the 
observed values from consensus random coil shifts are indicative of secondary 
structure. Indeed, positive or negative deviations in Cα are indicative of alpha-helical 
or beta-strand organization. It was recently shown that α‑Syn  has a propensity to 
adopt an alpha-helical secondary structure (up to 30%) in the first 15 residues.235 236 
Interestingly, in Met-oxidized AS this propensity decreased substantially, resulting in a 
highly disordered region (Figure2 C).To investigate whether Met oxidation can also 
modulate the membrane-binding features of α-syn, we tested the binding to small 
unilamellar vesicles (SUVs) made from polar pig-brain lipids. SUVs are useful lipidic 
models of synaptic vesicles, to which α‑Syn molecules bind in vivo.207 237 As reported, 
membrane-bound α‑Syn adopts different helical topologies, going from horse-shoe to 
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extended alpha-helical conformations in the first 100 residues.238 239 240 Common to all 
these conformations is the absence of membrane interactions of C-terminal α-syn 
residues 100-140. 
 
Figure 2. Reduced and oxidized α‑Syn SOFAST-HMQC spectra (A). The 1H-15N MWCS analysis of oxidized 
and reduced α‑Syn (B). C-alfa secondary chemical shifts for reduced and oxidized α‑Syn , whole 
sequence (upper) and first 15 residues (bottom),respectively(C). 
 
We prepared SUVsfrom polar pig-brain lipids and we verified that they were 
monodispersive with a size distribution around ~60 nm by DLS (Figure3 A). Next, we 
titrated SUVs to 15N isotope-labeled α-Syn reaching a 400-fold lipid:protein molar 
excess. NMR spectra revealed backbone amide line broadening of the first 100 amino 
acid residues, characteristic for α-Syn-membrane interactions. Interestingly, when we 
repeated these experiments using Met oxidized α‑Syn we detected a decreased 
affinity of oxidized versus reduced α‑Syn (Figure3 A-B). This differential binding to 
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SUVs is likely related with the decrease alpha helical propensity observed in oxidized α
‑Syn. 
 
Figure 3. Top left: overlapping of 2D 
1
H-
15
N HMQC spectra of N-terminally acetylated, but otherwise 
unmodified α-syn (black) and α-syn in the presence of 400-fold excess SUVs (green). Top right: 
Overlapping N-terminally acetylated and oxidized α-syn (azure) and oxi-α-syn in the presence of 400-
fold excess SUVs (green). (A). Residue-resolved plot of signal intensity ratios upon addition of SUVs to 
reduce and oxidized α-syn (400:1). Characteristic line-broadening of N-terminal α-syn residues (~1-100) 
is indicated Note that increased line broadening is observed for fully oxidized forms of the protein (B). 
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In-cell NMR of Met oxidized α‑Syn  
We followed an established electroporation protocol to introduce fully oxidized 15N 
uniformly labeled α‑Syn into the cytosol of non-neuronal (A2780, ovarian cancer, 
human) and neuronal (RSN3, dopaminergic neuron, rat) cell lines. Figure 4 shows the 
2D 1H-15N SOFAST-HMQC spectra of fully oxidized (cyan, 5 uM) and reduced (black, 5 
uM) α‑Syn in vitro and inside A2780 (Figure 4-A on the left) and RCSN3 (Figure 4-B on 
the right) cells. We also acquired NMR spectra of the supernatants of the cell slurries 
after the 2D experiments were finished (data not show). These spectra were 
completely empty confirming that the protein did not leaked out of the cells and that 
the signal obtained in the in-cell samples arises from intracellular α‑Syn.  
The 2D 1H-15N SOFAST-HMQC in-cell spectra of oxidized α‑Syn showed well resolved 
peaks with limited dispersion of 1HN chemical shifts indicating that the protein remains 
intrinsically disordered inside mammalian cells. As reported recently, the chemical 
shifts values of Leu8 of α‑Syn constitute and excellent probe for monitoring the 
oxidation states of Met1 and Met5.220 Other useful residues are those of Met1 and 
Met5 themselves, Asp2 and Lys6. For the C-terminal Methionines, Met127/Ser129 and 
Asp115/Met116 can be used to monitor M116 and M127 oxidation, respectively. The 
comparison of the In-cell spectra of oxidized α‑Syn with reference spectra of reduced 
and oxidized forms of the protein clearly showed that Met1 and Met5 residues were 
fully reduced inside A2780 and RCSN3 cells (Figure 4). This becomes evident if we 
compare the positions of the above mentioned residues with reference spectra of 
reduced and oxidized α‑Syn. In RCSN3 cells the signal to noise ratios obtained 
prevented an accurate analysis, however, the spectra were more clear after we 
performed lysis of the In-cell NMR samples (Figure S2, Supplementary data). 
Surprisingly, Met residues at positions 116 and 127 remained fully oxidized in A2780 
cells. This feature was also observed in RCSN3 cells but in this case we detected a small 
amount of reduced Met127, evidenced by the change of chemical shift position of 
S129 (Figure 4 and Figure S2, Supplementary data). 
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Figure 4. Overlapping of 
1
H-
15
N SOFAST-HMQC spectra of fully oxidized (cyan, 5 uM) and reduced (black, 
5 uM) α‑Syn in vitro and inside A2780 (red) (A) and RSN3 (B) cells, respectively. 
 
Because of the highly crowed regions where reduced and oxidized C-terminal Met 
residues show up in the 2D 1H-15N SOFAST HMQC spectra we decided to prepare 
15N/13C Met-only labeled α‑Syn. The In-cell NMR experiment of the Met-only labeled α
‑Syn clearly confirmed that the reduction occurs in the N-terminal methionine 
residues. (Figure 5) 
 
Figure 5 Overlapping of 
1
H-
15
N SOFAST-HMQC spectra of fully oxidized (cyan, 5 uM) and reduced (black, 
5 uM) in vitro and inside A2780 cells 
15
N/
13
C Met-only labeled α‑Syn.  
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Monitoring α‑Syn methionine repair in mammalian cell extracts by real time NMR. 
Due to the cell recovery step after the electroporation procedure and long acquisition 
of the In-cell NMR spectra we were not able to characterize the reduction process in a 
time resolved fashion by NMR. To overcome this problem we added oxidized α‑Syn to 
mammalian cell extracts. Mammalian cell extracts are less crowded and more 
homogenous than the cytosol of a cell and allow recording 1H-15N correlations within 
minutes.241,242 Initially, we added fully oxidized 15N uniformly labeled and 15N/13C Met-
only labeled α ‑ Syn (25uM) in a A2780 cell extract (10mg/ml total protein 
concentration) supplemented with 20mM DTT as electron source 243  and we 
immediately recorded 1H-15N HMQC spectra continuously for a period of 12hs (Figure 
6A-B). The labels o/o; o/r and r/r in the different panels refer to the oxidation state 
(reduced or oxidized) of Met1 and Met5, respectively. By integrating the signal of the 
differently oxidized α‑Syn species, we were able to delineate the reduction kinetic. 
Our results showed that Met5 was the most efficiently reduced residue (Figure 6C), 
followed by Met 1. We did not detected any resonances for α‑Syn where Met1 was 
reduced and and Met5 was still oxidized (r/o) indicating that the reduction of Met1 
occurs only after Met 5 was reduced or that the reduction of Met 5 is much faster than 
in our experimental conditions. A similar analysis performed on Met116 and Met127 
revealed that these residues are not significantly repaired, in full agreement with our 
previous in-cell NMR results.  
We repeated these experiments with RCNS3 and other neuronal and non-neuronal 
mammalian cell extracts (FigureS3, Supplementary data). The results showed the same 
hierarchy of reduction in all cell extract assayed. 
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Figure 6. RT-NMR observations of fully oxidized 
15
N uniformly labeled and 
15
N/
13
C Met-only labeled α‑
Syn (25uM) repair in a A2780 cell extract (10mg/ml) total protein concentration (A-B). α‑Syn 
methionines repair reduction kinetic in the same extract. Upper chart, N-terminal M1 and M5 reduction 
kinetic (o/o, balck; o/r, red; and r/r brownish-yellow) and lower  chart, C-terminal M127 (dark-gray) and 
M116 (green). 
 
Methionine sulfoxide reductase (MSR) enzymes target Met oxidized α‑Syn. 
Next, we try to identify the cellular components responsible for reducing Met residues 
in our In-cell NMR and extract samples. It was recently shown that a specific family of 
enzymes, called methionine sulfoxide reductase (MSRs), is able to catalyze the 
reduction of Met sulfoxides to the normal Met sidechain.244,245,246 In human, the MSR 
family is mainly divided in two sub-groups: MSRA, which selectively repair MetO-R 
diastereoisomer and MSRB that reduce the MetO-S diastereoisomer. In particular, it 
was shown that MSRA can reduce oxidized α‑Syn  and its overespression protects 
cultured neuronal cells from oxidative insults elicited by rotenone.247 These enzymes 
catalyze the removal of the oxygen from the sulphur atom of a Met residue at the 
expense of their oxidation and further regerenration by the NADPH dependent 
thioredoxin (TRX)/thioredoxing reductase (TRXR) system. 248 249 Accordingly, we 
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investigated if MSRA and other members of MSR family were present in the cells we 
used for our experiments by inmunobloting techniques. We detected all the players of 
the MSR/TRX/TRXR system (Figure 7 A-B). In addition, we repeated the repair kinetics 
in the presence of increasing concentration of DMSO, a known inhibitor MSRs.250,251 
Our results showed that the repair of Met5 was impaired by DMSO in a concentration 
dependent fashion. Finally, incubation of fully oxidized α‑Syn with DTT alone or an 
extract that was preboiled or DEPC treated to destroy. any enzymatic activity resulted 
in non repair (Figure 7 C-D). Altogether, these results strongly suggest that oxidized 
Met 1 and 5 residues in our cell and extract experiments are reduced by the MSR 
enzymes. 
 
Figure 7. The MSRs/TRX)/TRXR system (A).Western blots of endogenous MSRs(A,B1,B2,B3A isoforms) 
and TRX in lysates of cultured mammalian A2780, and RCSN-3 cells (B) MetOxi5 repair kinetics in the 
presence of increasing concentration of DMSO (C) Overlapping of 
1
H-
15
N SOFAST-HMQC spectra of 
oxidized (cyan) and after the incubation of fully oxidized α‑Syn with DTT alone on the left, and  after the 
incubation of fully oxidized α‑Syn into an extract that was preboiled or DEPC treated to destroy (D) 
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DISCUSSION 
We applied novel In cell, in extracts and in vitro NMR spectroscopy techniques to study 
the intracellular fate of oxidized α‑Syn molecules. In particular, from our in vitro 
experiments on methionine oxidized and reduced α‑Syn samples, we showed that 
oxidation doesn’t induce large conformational rearrangements of α‑Syn, however, it 
affects the local conformation of the oxidized regions, especially at the N-terminus, 
even compromising the membrane binding ability of α‑Syn.  
Although, using in cell and in extract RT-NMR spectroscopy, first we were able to prove 
in all the used cell lines that the N-terminal Methionine are completely repaired in 
several cell lines, proving how cells are able to repair a damage that could compromise 
the protein structural functionality inside themselves, and second the C terminal 
Met116 and Met127 are not significantly repaired. Both evidences point out that 
might be the C-terminal region involved into the link between the pathological 
aggregation and oxidative stress, in particular it could represent an explanation to the 
known correlation between oxidative stress and increased S129 phosphorylation 
levels.252 In fact S129-phosphorylated is a pathological hallmark of PD. This PTM is 
abundantly (90%) found in Lewy-body inclusions of Parkinson’s disease patients, 
whereas the soluble protein is barely modified (less than 4%), which supports a 
possible link between α-syn S129 phosphorylation, protein aggregation and PD 
pathogenesis.253,254 
Evidences showed crosstalk between S129 phosphorylation and other PTMs in the 
neighboring residues. In particular, it was recently demostrated that Y125 
phosphorylation constitutes a necessary priming event for the efficient modification of 
S129 by Casein Kinase1.255 
In addiction some studies also showed how in nature is it possible a crosstalk between 
phosphorylation and Met oxidation in the neighboring residues. For example, site-
specific oxidation of Met in calmodulin was shown to affect its structure, and thus its 
interaction with Ca2+/calmodulin-dependent protein kinase II and subsequent 
downstream signaling.256 All the proteins containing these phosphorylation sites which 
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include a vicinal Met residue can potentially function as redox sensors capable of 
transducing input from ROS signalling to regulation of phosphorylation. 
Expecially for α ‑ Syn, S129 phosphorylation on non-aggregated protein form 
represents a balance between kinase and phosphatase activities. Under physiological 
conditions, phosphatases probably outweighing kinases activity, keeping a low cellular 
concentration of S129 α‑Syn. Since, C-teminal Methionines (above all M127) are not 
so far from S129, an oxidative stress could induce a-syn methionine oxidation, and 
consequently the not repaired C-terminus methionines may shift the equilibrium 
toward the preservation of S129 phosphorylation. This could be explained from the 
fact that Met oxidation causes a shift from hydrophobic to hydrophilic in nature, and 
would thus likely disrupt enzyme recognition.257 
CONCLUSIONS 
In summary, here is showed that NMR spectroscopy is able to show how methionine-
oxidized a-syn in different cell lines undergoes site-selective repair by endogenous 
enzymes. In oxidized α-Syn, Met5 is the preferred substrate, followed by Met1, 
whereas C-terminal Met116 and Met127 are likely to remain oxidized. These results 
indicate that cellular oxidative modifications in the form of Met-sulfoxides at the C-
terminal region of α‑Syn, it might contribute the abnormal accumulation of S129 α‑
Syn and into the consequent formation of the toxic aggregates present in PD patients. 
These knowledge represent a step forwards for understanding the molecular basis of 
synucleinopathies and it could represent a starting point for developing tools to 
diagnose and monitor the progression of these diseases, and assessing the 
effectiveness of preventive and therapeutic strategies. 
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EXPERIMENTAL SECTION 
Protein and reagents. 15N isotopically enriched, N-terminally acetylated AS was 
obtained by co-expressing the wild-type AS plasmid (pT-T7) and the plasmid harboring 
the yeast NatB acetylase complex258 in E. Coli BL21 (DE3) Express. The transfected 
bacteria were grown in M9 minimal media supplemented with 15N NH4Cl (Sigma) 
and/or 13C uniformly labeled D-glucose (Sigma) until an OD600 of 0.6 and induced with 
1 mM IPTG (Roth). Overexpression was performed overnight at 30oC. For 15N/13C Met-
only labeled species we supplemented the M9 minimal media with natural abundance 
NH4Cl and D-glucose 0.3 mM of 
13C5, 15N labeled L-methionine (Isotec, 608106) as 
previously reported.259 Proteins were purified as previously described 260,261 and their 
purity was evaluated by SDS-PAGE. N-terminal acetylation was complete in all samples 
as determined by 1H-15N SOFAST-HMQC experiments. Methionine oxidized AS samples 
were prepared by incubating 500 μM AS with 4% H2O2 (Sigma)
232 for 2 hours and 
subsequent purification by size-exclusion chromatography to remove the H2O2 excess. 
Complete elimination of peroxide was additionally verified using a colorimetric 
detection assay (Enzo Life Sciences). We confirmed exhaustive methionine oxidation 
by 2D 1H-15N SOFAST-HMQC experiments. AS samples were dissolved in 20 mM 
phosphate buffer, pH 7.0, 150 mM NaCl and 10% D2O (i.e. NMR buffer) and their 
concentrations were determined spectrophotometrically by absorption measurements 
at 274 nm (ε = 5600 M-1cm-1). 
Circular dichroism (CD). CD measurements were performed with a Jasco J-720 
spectropolarimeter at 25oC on 10 μM AS samples dissolved in NMR buffer at pH 7.0. 
Far-UV CD spectra were collected using a 0.1 cm path-length cuvette. 8 scans were 
averaged and blank (buffer) spectra were subtracted from the spectra to calculate the 
ellipticity values (mdeg). 
Size exclusion chromatography (SEC). For SEC experiments 200 μl, 500 μM of AS 
samples were injected into a Superdex 75 analytical column (GE Healthcare) connected 
to an AKTA purifier FPLC machine (GE Healthcare). To obtain the SEC profiles the 
absorbance at 280 nm was plotted as a function of the eluted volume. In all cases 
elution volumes were set to zero at injection. 
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Dynamic light scattering (DLS). DLS was performed on a Malvern Zetasizer 
Nano machine operating at a laser wavelength of 633 nm at 25oC in 3x3 mm cuvettes 
and 50 mM AS samples dissolved in NMR buffer. Hydrodynamic radii were calculated 
based on volume weighted analyses of scattered light, using the Malvern DTS 
software. 
Preparation small unilamellar vesicles (SUVs). SUVs were prepared using 
naturally occurring pig brain lipids.  Lyophilized pig brain polar lipid extract was bought 
from Avanti Polar Lipids (Alabaster, USA) and SUVs were prepared in NMR buffer by 
freeze-thaw and sonication as previously described.262 Initial stock solutions were 
adjusted to 20 mM considering the total lipid input. Average vesicles sizes of 60 nm 
were determined by dynamic light scattering (DLS).  
NMR spectroscopy. Assignment of reduced and fully Met-oxidized AcAS was 
performed on 500 μM protein samples dissolved in NMR buffer at pH 7.0. We 
recorded 1H-15N SOFAST-HMQC 234experiments and triple resonance HNCACB and 
CBCACONH (Bruker standard pulse sequences) at 15o C on a 750 MHz Bruker Avance 
spectrometer, equipped with a cryogenically cooled triple resonance 1H(13C/15N) TCI 
probe. Parameters used were 1024 (1H) and 256 (15N) complex points for a SW of 16 
ppm (1H) and 26 ppm (15N) and 16 scans for 2D 1H-15N SOFAST-HMQC experiments. For 
3D HNCACB and CBCACONH experiment we used 1024 (1H), 72 (15N) and 96 (13C) 
complex points  for a SW of 16 ppm (1H), 26 ppm (15N) and 70 ppm (13C) and 16 scans. 
Pulse sequences and its parameters were used as described previously. 234,241} NMR 
spectra were zero-filled to 4-times the number of real points and processed using a 
sine window function and baseline correction for all dimensions. Backbone 
assignments were performed with CARA (Computer-Aided Resonance Assignment, 
Institute for Molecular Biology and Biophysics, Zürich Switzerland). NMR spectra of 
SUV-bound protein samples were performed on 50 μM protein samples at 30oC to 
improve signal to noise ratios. 
 In-cell NMR spectra were acquired on 600 MHz and 900 MHz Bruker Avance 
spectrometers, equipped with cryogenically cooled triple resonance 1H(13C/15N) TCI 
probes. All In-cell spectra were performed at 10oC. Parameters used for 2D 1H-15N 
SOFAST-HMQC In-cell spectra were 1024 (1H) and 256 (15N) complex points, 128 scans 
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and 60 ms of recycling delay for A2780 In-cell samples and 1024 (1H) and 128 (15N) 
complex points, 2K scans and 60 ms of recycling delay for RCSN3 In-cell samples. SW 
used were 16 ppm (1H) and 26 ppm (15N) for 15N uniformly labeled oxidized AS and 16 
ppm (1H) and 14 ppm (15N) for 15N/13C Met-only labeled samples. 1D 1H-15N SOFAST-
HMQC spectra were acquired in the same conditions but using 4K scans. Spectra were 
processed by zero-filling to 4-times the number of real points and by employing sine-
modulated window functions in all dimensions.  
 Time-resolved NMR spectra of reduction kinetics were recorded on 600 MHz 
and 750 MHz Bruker Avance spectrometers, equipped with cryogenically cooled triple 
resonance 1H(13C/15N) TCI probes, on Met-oxidized AS samples in NMR buffer at pH 
7.0. 1D and 2D 1H-15N SOFAST-HMQC experiments were recorded at 25o C. All time-
resolved 2D NMR spectra were recorded with 1024 (1H) and 128 (15N) complex points, 
96 scans and a recycling delay of 60 ms (~ 20 minutes acquisition time). Spectra were 
processed by zero-filling to 4-times the number of real points and by employing sine-
modulated window functions in all dimensions. To delineate Met-sulfoxide reduction 
rates, we measured cross-peak intensities and/or signal volumes of unambiguously 
assigned, well-resolved NMR cross-peaks reporting on the individual oxidation states 
of Met1, Met5, Met116 and Met127 in the different time-resolved NMR spectra, as 
reported previously. 241 These were Met1, Asp2, Met5, Lys6, Gly7 and Leu8 for M1 and 
M5; Asp115 and Met116 for Met116 and Met127 and Ser129 for Met127. Acquisition, 
processing and visualization of NMR spectra were performed with TOPSPIN 3.1 
(Bruker) and SPARKY 263  Weighted chemical shift differences were obtained as 
previously described.264 Secondary shift values were calculated as the differences 
between the measured Cα chemical shifts and the empirical random coil values 
reported by Wishart et al.265 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) was 
employed for chemical shift referencing. NMR signal intensity ratios (I/I0) were 
determined for ~110 unambiguosly assigned, non-overlapped cross-peaks of oxidized 
and reduced AS by quantifying their intensity in the presence (I) or absence (I0) of 
SUVs. Error bars in the time-resolved reaction profiles represent the relative 
experimental noise of the individual NMR signals used to calculate the site-specific 
oxidation states. 
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 Fitting of kinetic of repair curves. Time course of Met reduction were fitted by 
an exponential increase or decay and plotted using GraphPad Prism 5.0. Error bars in 
the time-resolved reaction profiles represent the relative experimental noise of the 
individual NMR signals used to calculate the site-specific oxidation states. 
In-cell NMR sample preparation. Briefly, A2780 and RCSN-3 cells were grown at 
37oC, 5% CO2, in T175 culture flasks with RPMI (Millipore, FG1215) and DMEM-HAM‘s 
F-12 (Biochrom, FG4815), respectively, supplemented with 10% fetal bovine serum 
(Biochrom, S0615) until 80% confluence was reached. For each in-cell NMR sample we 
collected 50-100x106 cells by mild trypsin treatment (Biochrom, L2153) and 
resuspended them in 2 ml electroporation buffer (100 mM sodium phosphate, 15 mM 
Hepes, 5 mM KCl, 15 mM MgCl2, 2 mM ATP, 2 mM reduced gluthatione, pH 7.0) 
containing 500 μM of fully oxidized AS uniformly labeled with 15N or in a 15N/13C Met-
only labeled form. The suspension was aliquoted in 100 ul fractions and electroporated 
using an Amaxa nucleofector device (Lonza) according to the manofacturer´s 
instructions. Cells were replated in 15 cm culture dishes and placed in the incubator 
for 4 hs for their recovery. After that dishes were washed 3X with pre-warmed PBS to 
discard death cells, collected by mild tripsin treatment, washed 2X with the 
corresponding pre-warmed growth media to remove excess of trypsin and 
resuspended in pH stable Leiwobitz (Gibco, 31415-029) media supplemented with 10% 
D2O. Then, cells were gently transferred to the NMR for spectra acquisition 
Preparation of cell lysates. Cells grown at 37oC, 5% CO2, in T175 culture flasks 
until ~ 80% confluence, detached by trypsin treatment, washed twice with PBS and 
resuspended in NMR buffer containing 1X protease inhibitors (complete EDTA-free, 
Roche). Cells were centrifuged for 5 min. at 1000 rpm and the supernatant was 
discarded. The wet cell pellet was lyzed by 5 rounds of freeze-thaw using a dry 
ice/ethanol bath, after which the soluble fractions were obtained by a 10 min spin at 
16,000 g at 4 oC. Full lysis was confirmed by tripan blue staining and cell count and 
protein concentrations were determined using a Bradford assay (Bio-Rad). Extracts 
were used immediately after preparation or aliquoted and snap-frozen in liquid 
nitrogen and stored at -80o C until further use. Freeze-thaw cycles were avoided in 
order to preserve enzymatic activities.241 Samples for Western Blotting were boiled for 
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15 minutes in 1X Laemmli buffer (Bio-Rad). Mammalian cell lines were: A2780 (human, 
ovarian, Sigma-Aldrich), B65 (rat, neuroblastoma, Sigma Aldrich), SH-SY5Y (human, 
neuroblastoma, provided by Jan Bieschke, MDC-Berlin), RCSN-3 (rat, substantia nigra, 
Pablo Caviedes, University of Chile), SK-N-SH (human, neuroblastoma, Sigma-Aldrich) 
and Hela (human, cervical cancer, Sigma).  
Reduction assays. For reduction reactions, extracts were adjusted to 10 mg/ml 
total protein concentration in NMR buffer and supplemented with 20 mM DTT 
Applichem). Reactions were carried out in duplicates at 25o C by spiking 25 μM of 
uniformly 15N or 15N/13C Met-only labeled AS into the different cell lysates and 
immediately starting the NMR experiments. For some experiments we added 
increasing amounts of deuterated DMSO (Euriso-top) before starting acquisitions. In all 
cases total reaction volumes were 150 ul. Reactions were performed inside 3 mm 
Shigemi tubes.  
Western blots. Samples were separated by SDS-PAGE using 4-20% gradient gels 
(Bio-Rad) and transferred onto PVDF membranes. Blots were blocked in 5% milk in 
TBS-T for 1 hour at room temperature, before incubating them overnight at 4o C with 
the following primary antibodies: anti-MSRA (1:1000, Abcam, ab16803), anti-MSRB1 
(1:200, Abcam, ab66061), anti-MSRB2 (1:500, Abcam, ab101513), anti-MSRB3 (1:500, 
Abcam, ab88731) anti-TRX (1:1000, Abcam, ab86255), anti TRXreduct (1:500, Abcam, 
ab16847) or anti-β-Actin (1:5000, Abcam, ab6276). Membranes were incubated with 
HRP secondary antibodies for 1 hr. at room temperature and probed using SuperSignal 
West Pico chemiluminescent substrate (Thermo Scientific). Luminescence was 
detected using a Bio-Rad Molecular Imager and ImageLab software. 
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SUPPLEMETARY DATA 
 
Figure S1. The treatment with 4% H2O2 for 1 hour at room temperature results in the oxidation of all 
Met residues to corresponding sulfoxide species (A). Biophysical properties of oxidized and reduced α‑
Syn. Circular dichroism (CD), dynamic light scattering (DLS) and SEC experiments. 
 
Figure S2. Lysate spectra of the in-cell NMR samples (Fig 4). Overlapping of 
1
H-
15
N SOFAST-HMQC 
spectra of fully oxidized (cyan, 5 uM) and reduced (black, 5 uM) α‑Syn in vitro and in extract A2780 (red) 
(A) and RSN3 (B) cells, respectively. 
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Figure S3. RT-NMR: α‑Syn methionine repair reduction kinetic in different cell extracts . The total 
protein concentration was 10mg/ml, for all the extracts used. 
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